

Schizophrenia and increased risks of cardiovascular dis

American Heart Journal

150, 1115-1121

DOI: [10.1016/j.ahj.2005.02.007](https://doi.org/10.1016/j.ahj.2005.02.007)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cardiac risk management in severe mental illness. <i>Lancet</i> , The, 2006, 367, 1469-1471.	6.3	1
2	Altered diurnal autonomic variation and reduced vagal information flow in acute schizophrenia. <i>Clinical Neurophysiology</i> , 2006, 117, 2715-2722.	0.7	96
4	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006, 86, 15-22.	1.1	473
6	Schizophrenia and increased risk of cardiovascular disease. <i>American Heart Journal</i> , 2006, 151, e13.	1.2	10
7	Smoke-free legislation and mental health units: the challenges ahead. <i>British Journal of Psychiatry</i> , 2006, 189, 479-480.	1.7	37
8	Physical health and schizophrenia. <i>Current Opinion in Psychiatry</i> , 2006, 19, 432-437.	3.1	89
9	Metabolic Monitoring for Patients Treated with Antipsychotic Medications. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 492-501.	0.9	139
10	Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated with Antipsychotic Medications. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 502-511.	0.9	71
12	Mortality in schizophrenia. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 873-879.	0.9	133
13	Smoke, Smoke, Smoke That Cigarette. <i>Perspectives in Psychiatric Care</i> , 2006, 42, 256-261.	0.9	28
14	A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients. <i>Schizophrenia Bulletin</i> , 2006, 33, 1397-1403.	2.3	119
15	Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2007, 3, 113-150.	0.7	6
16	A Systematic Review of Mortality in Schizophrenia. <i>Archives of General Psychiatry</i> , 2007, 64, 1123.	13.8	1,770
17	<i>Toxoplasma gondii</i> in Individuals With Schizophrenia: Association With Clinical and Demographic Factors and With Mortality. <i>Schizophrenia Bulletin</i> , 2007, 33, 737-740.	2.3	58
18	Considering the Impact on Overall Patient Health When Choosing Antipsychotic Therapy. <i>Journal of the American Psychiatric Nurses Association</i> , 2007, 13, S23-S28.	0.4	2
19	Balancing Efficacy and Safety in Treatment with Antipsychotics. <i>CNS Spectrums</i> , 2007, 12, 12-20.	0.7	64
20	An Outcome Measure in Schizophrenia: Mortality. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 55-60.	0.9	27
21	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 2007, 22, 249-267.	0.9	46

#	ARTICLE	IF	CITATIONS
22	Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. <i>International Clinical Psychopharmacology</i> , 2007, 22, 363-370.	0.9	44
23	Moving Towards Smoke-free Mental Health Services. <i>Mental Health Review Journal</i> , 2007, 12, 18-24.	0.3	2
24	Medical problems in schizophrenia patients living in the community (alternative facilities). <i>Current Opinion in Psychiatry</i> , 2007, 20, 402-405.	3.1	16
25	Guide Schizophrenia Patients to Better Physical Health. <i>Nurse Practitioner</i> , 2007, 32, 30-37.	0.2	4
26	Medical comorbidity in bipolar disorder: reprioritizing unmet needs. <i>Current Opinion in Psychiatry</i> , 2007, 20, 406-416.	3.1	114
27	Epidemiology of Comorbid Tobacco Use and Schizophrenia: Thinking About Risks and Protective Factors. <i>Journal of Dual Diagnosis</i> , 2007, 3, 9-25.	0.7	15
28	Point prevalence of diabetes, obesity, hyperlipidaemia, hypertension and smoking in outpatients on clozapine. <i>Irish Journal of Psychological Medicine</i> , 2007, 24, 59-61.	0.7	2
29	Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al.. <i>Psychological Medicine</i> , 2007, 37, 913-916.	2.7	17
30	Abnormal glucose metabolism in patients treated with antipsychotics. <i>Diabetes and Metabolism</i> , 2007, 33, 169-175.	1.4	146
31	Elevated plasma N-terminal ProBNP levels in unmedicated patients with major depressive disorder. <i>Neuroscience Letters</i> , 2007, 417, 322-325.	1.0	18
33	Reaching for Wellness in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 453-479.	0.7	16
34	Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. <i>Journal of Psychopharmacology</i> , 2007, 21, 857-863.	2.0	42
35	Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. <i>Current Medical Research and Opinion</i> , 2007, 23, 1733-1744.	0.9	23
36	Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. <i>Schizophrenia Research</i> , 2007, 95, 115-123.	1.1	85
37	Drug-Induced Cardiovascular Disorders. <i>Drug Safety</i> , 2007, 30, 783-804.	1.4	32
38	Decreased baroreflex sensitivity in acute schizophrenia. <i>Journal of Applied Physiology</i> , 2007, 102, 1051-1056.	1.2	86
39	Prevalence of tobacco use in individuals with severe mental illnesses, São Paulo, Brazil. <i>Revista De Saude Publica</i> , 2007, 41, 510-516.	0.7	6
40	Associations of blood homocysteine concentrations in Arab schizophrenic patients. <i>Clinical Biochemistry</i> , 2007, 40, 1026-1031.	0.8	32

#	ARTICLE	IF	CITATIONS
41	The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness. <i>Patient Education and Counseling</i> , 2007, 66, 123-126.	1.0	35
42	How do General Practitioners experience providing care for their psychotic patients?. <i>BMC Family Practice</i> , 2007, 8, 37.	2.9	31
43	Cardiovascular risks of atypical antipsychotic drug treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 882-890.	0.9	64
44	Helping adults with schizophrenia or schizoaffective disorder stop smoking resulted in positive short-term health benefits. <i>Australian Occupational Therapy Journal</i> , 2007, 54, 75-76.	0.6	0
45	Assessment of the performances of multilayer perceptron neural networks in comparison with recurrent neural networks and two statistical methods for diagnosing coronary artery disease. <i>Expert Systems</i> , 2007, 24, 131-142.	2.9	22
46	Physical illness and schizophrenia: a review of the literature. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 317-333.	2.2	545
47	A well-being programme in severe mental illness. Baseline findings in a UK cohort. <i>International Journal of Clinical Practice</i> , 2007, 61, 1971-1978.	0.8	53
48	Residential mobility of individuals with diagnosed schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 221-228.	1.6	25
49	Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. <i>Psychopharmacology</i> , 2008, 200, 317-331.	1.5	59
50	Olanzapine metabolic side effects: a weight gain issue?. <i>Internal and Emergency Medicine</i> , 2008, 3, 237-240.	1.0	2
51	Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. <i>BMC Psychiatry</i> , 2008, 8, 76.	1.1	15
52	Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis. <i>BMC Psychiatry</i> , 2008, 8, 84.	1.1	161
53	A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. <i>Acta Psychiatrica Scandinavica</i> , 2008, 118, 246-250.	2.2	16
54	Nutrition and mental health research: Where to from here?. <i>Nutrition and Dietetics</i> , 2008, 65, 4-5.	0.9	2
55	Establishing an innovative model of nutrition and dietetic care for a mental health service through collaboration with non-nutrition healthcare workers. <i>Nutrition and Dietetics</i> , 2008, 65, 279-283.	0.9	1
56	Adverse Hospital Events for Mentally Ill Patients Undergoing Coronary Artery Bypass Surgery. <i>Health Services Research</i> , 2008, 43, 2239-2252.	1.0	19
57	Time to wake up and smell the coffee: antipsychotic medication and schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 344-348.	1.2	11
58	Quantifying links between acute myocardial infarction and depression, anxiety and schizophrenia using case register databases. <i>Journal of Affective Disorders</i> , 2008, 109, 177-181.	2.0	48

#	ARTICLE	IF	CITATIONS
59	Physical health in schizophrenia and related disorders. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 472-476.	0.2	4
60	Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. <i>Schizophrenia Research</i> , 2008, 98, 287-294.	1.1	174
61	Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. <i>Schizophrenia Research</i> , 2008, 101, 287-294.	1.1	53
62	An increased risk of stroke among young schizophrenia patients. <i>Schizophrenia Research</i> , 2008, 101, 234-241.	1.1	64
63	Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. <i>Schizophrenia Research</i> , 2008, 101, 295-303.	1.1	217
64	Telomerase levels in schizophrenia: A preliminary study. <i>Schizophrenia Research</i> , 2008, 106, 242-247.	1.1	48
65	A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2008, 106, 308-314.	1.1	40
66	Antipsicóticos atípicos: un factor de riesgo de síndrome metabólico. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2008, 55, 61-63.	0.8	0
67	The interaction between pupil function and cardiovascular regulation in patients with acute schizophrenia. <i>Clinical Neurophysiology</i> , 2008, 119, 2209-2213.	0.7	65
68	Antipsychotic Medication-Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease. , 2007, , 223-245.		1
70	Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1527-1532.	2.5	25
72	Traditional Chinese medicine usage among schizophrenia patients. <i>Complementary Therapies in Medicine</i> , 2008, 16, 336-342.	1.3	17
73	Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controls. <i>NeuroImage</i> , 2008, 40, 1181-1194.	2.1	29
74	Management of physical health in schizophrenia: A stepping stone to treatment success. <i>European Neuropsychopharmacology</i> , 2008, 18, S121-S128.	0.3	25
75	Limitations of current therapies: Why do patients switch therapies?. <i>European Neuropsychopharmacology</i> , 2008, 18, S135-S139.	0.3	10
76	Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. <i>Schizophrenia Research</i> , 2008, 100, 252-260.	1.1	70
77	Heart rate variability response to mental arithmetic stress in patients with schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 294-303.	1.1	65
78	Traitements neuroleptiques et troubles métaboliques. <i>Medecine Des Maladies Metaboliques</i> , 2008, 2, 593-599.	0.1	4

#	ARTICLE	IF	CITATIONS
79	Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?. Schizophrenia Research, 2008, 102, 329-336.	1.1	101
80	Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand. Annals of Pharmacotherapy, 2008, 42, 852-860.	0.9	75
81	Is Schizophrenia a Syndrome of Accelerated Aging?. Schizophrenia Bulletin, 2008, 34, 1024-1032.	2.3	258
82	The Time to Act Is Now: APNA's Commitment to Smoking Cessation in Persons With Major Mental Illness. Journal of the American Psychiatric Nurses Association, 2008, 14, 266-268.	0.4	1
83	Evaluating the association between clozapine and venous thromboembolism. American Journal of Health-System Pharmacy, 2008, 65, 1825-1829.	0.5	37
84	Implementing Smoke-Free Policies in Mental Health Inpatient Units: Learning from Unsuccessful Experience. Australasian Psychiatry, 2008, 16, 92-97.	0.4	41
85	The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Neuropsychopharmacology, 2008, 33, 2061-2079.	2.8	183
86	Physical health—a cluster randomized controlled lifestyle intervention among persons with a psychiatric disability and their staff. Nordic Journal of Psychiatry, 2008, 62, 486-495.	0.7	64
88	Physical health and attendance at primary care in people with schizophrenia. Irish Journal of Psychological Medicine, 2008, 25, 57-60.	0.7	2
89	Smoking by people with mental illness and benefits of smoke-free mental health services. Advances in Psychiatric Treatment, 2008, 14, 217-228.	0.6	66
90	Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics. Focus (American Psychiatric Publishing), 2008, 6, 172-179.	0.4	3
91	The Urgent Need for Monitoring and Intervention to Reduce Metabolic Risk Factors in Patients with Schizophrenia. CNS Spectrums, 2008, 13, 5-6.	0.7	1
92	Prevention of Premature Mortality Among Patients with Schizophrenia: The Need for Primary Prevention Efforts in Cardiovascular Disease. CNS Spectrums, 2008, 13, 9-10.	0.7	3
93	Influence of Olanzapine on QT Variability and Complexity Measures of Heart Rate in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, 694-698.	0.7	40
94	Clinical Trial of Wellness Training. Journal of Nervous and Mental Disease, 2008, 196, 475-483.	0.5	36
95	Diretrizes para cessação do tabagismo - 2008. Jornal Brasileiro De Pneumologia, 2008, 34, 845-880.	0.4	118
96	METABOLIC SYNDROME AND PSYCHIATRIC ILLNESS. , 2008, , 49-72.		15
97	Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Medical Journal of Australia, 2009, 190, S39-42.	0.8	100

#	ARTICLE	IF	CITATIONS
98	Qigong as a mindful exercise intervention for people living with mental ill health. <i>International Journal of Therapy and Rehabilitation</i> , 2009, 16, 393-399.	0.1	6
99	Antipsychotics and risk of venous thromboembolism: A population-based case-control study. <i>Clinical Epidemiology</i> , 2009, 1, 19.	1.5	34
100	Screening for and monitoring of cardio-metabolic risk factors in outpatients with severe mental illness in a primary care setting. <i>African Journal of Psychiatry</i> , 2009, 12, 287-92.	0.1	4
101	Serotonin 5- Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. <i>Cardiovascular Psychiatry and Neurology</i> , 2009, 2009, 1-8.	0.8	31
102	Barriers to uptake of physical activity in community-based patients with schizophrenia. <i>Journal of Mental Health</i> , 2009, 18, 523-532.	1.0	63
103	Metabolic Risk Factors Among Medicaid Outpatients With Schizophrenia Receiving Second-Generation Antipsychotics. <i>Psychiatric Services</i> , 2009, 60, 1686-1689.	1.1	45
105	Psychiatric Nurses as Champions for Smoking Cessation. <i>Journal of the American Psychiatric Nurses Association</i> , 2009, 15, 21-23.	0.4	10
107	Cardiometabolic effects of physical activity interventions for people with schizophrenia. <i>Physical Therapy Reviews</i> , 2009, 14, 388-398.	0.3	48
108	Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 420-425.	1.3	30
109	Health Care for Patients with Serious Mental Illness: Family Medicine's Role. <i>Journal of the American Board of Family Medicine</i> , 2009, 22, 187-195.	0.8	71
110	Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. <i>Journal of Psychopharmacology</i> , 2009, 23, 697-707.	2.0	29
111	Assessment of a Point-of-Care Metabolic Risk Screening Program in Outpatients Receiving Antipsychotic Agents. <i>Pharmacotherapy</i> , 2009, 29, 975-987.	1.2	35
112	Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. <i>General Hospital Psychiatry</i> , 2009, 31, 555-563.	1.2	158
113	UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 239-247.	1.8	17
114	Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. <i>BMC Family Practice</i> , 2009, 10, 32.	2.9	102
115	A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 457-465.	2.2	38
116	Lifestyles and Cardiovascular Risk in Individuals With Functional Psychoses. <i>Perspectives in Psychiatric Care</i> , 2009, 45, 87-99.	0.9	20
117	Autonomic nervous system activity and psychiatric severity in schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 538-545.	1.0	55

#	ARTICLE	IF	CITATIONS
118	Differential pattern of heart rate variability in patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 991-995.	2.5	53
119	The impact of mental illness on cardiac outcomes: A review for the cardiologist. <i>International Journal of Cardiology</i> , 2009, 132, 30-37.	0.8	65
120	Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. <i>Schizophrenia Research</i> , 2009, 107, 134-138.	1.1	26
121	Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study. <i>Schizophrenia Research</i> , 2009, 111, 1-8.	1.1	68
122	Insulin resistance and schizophrenia: Results from the Northern Finland 1966 Birth Cohort. <i>Schizophrenia Research</i> , 2009, 113, 107-108.	1.1	5
123	Biochemical risk factors for development of obesity in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2009, 115, 141-145.	1.1	13
124	From mice to men: What can animal models tell us about the relationship between mental health and physical activity?. <i>Mental Health and Physical Activity</i> , 2009, 2, 10-15.	0.9	22
125	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2009, 2, 49-59.	0.2	10
126	Metabolic syndrome in people with schizophrenia: a review. <i>World Psychiatry</i> , 2009, 8, 15-22.	4.8	495
127	Management of Schizophrenia with Medical Disorders: Cardiovascular, Pulmonary, and Gastrointestinal. <i>Psychiatric Clinics of North America</i> , 2009, 32, 759-773.	0.7	7
128	Management of smoking cessation in patients with psychiatric disorders. <i>Current Medical Research and Opinion</i> , 2009, 25, 511-518.	0.9	79
129	Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. <i>European Psychiatry</i> , 2009, 24, 154-163.	0.1	8
130	Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area. <i>European Psychiatry</i> , 2009, 24, 431-441.	0.1	50
131	Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders. <i>Psychiatric Clinics of North America</i> , 2009, 32, 775-794.	0.7	44
132	Providing primary care for people with serious mental illness. <i>Primary Health Care Research and Development</i> , 2009, 10, 81.	0.5	0
133	Current approaches to the management of schizophrenia. <i>Irish Journal of Psychological Medicine</i> , 2009, 26, i-vii.	0.7	2
134	Mechanisms Underlying the Comorbidity of Tobacco Use in Mental Health and Addictive Disorders. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 356-367.	0.9	77
135	Addressing Tobacco Dependence in Psychiatric Practice: Promises and Pitfalls. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 353-355.	0.9	21

#	ARTICLE	IF	CITATIONS
136	Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2175.	0.1	4
137	Quality of Care for Cardiometabolic Disease. <i>Medical Care</i> , 2010, 48, 72-78.	1.1	10
138	Metabolic syndrome with the atypical antipsychotics. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 460-466.	1.2	149
139	How Sequential Studies Inform Drug Development: Evaluating the Effect of Food Intake on Optimal Bioavailability of Ziprasidone. <i>Journal of Psychiatric Practice</i> , 2010, 16, 103-114.	0.3	23
140	Why do patients with schizophrenia smoke?. <i>Current Opinion in Psychiatry</i> , 2010, 23, 112-119.	3.1	203
141	Cardiovascular aspects of antipsychotics. <i>Current Opinion in Psychiatry</i> , 2010, 23, 574-581.	3.1	72
142	Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2010, 33, 121-125.	0.2	28
143	Pharmacotherapy of First-Episode Schizophrenia. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2010, 45, 41-48.	0.1	1
144	Pharmacotherapy of First-Episode Schizophrenia. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2010, 45, 48.	0.1	0
145	General Medical Problems of Incarcerated Persons With Severe and Persistent Mental Illness: A Population-Based Study. <i>Psychiatric Services</i> , 2010, 61, 45-49.	1.1	31
146	Regional Differences in Five-Year Mortality After a First Episode of Schizophrenia in Finland. <i>Psychiatric Services</i> , 2010, 61, 272-279.	1.1	20
147	The Epidemiology of Excess Mortality in People with Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 752-760.	0.9	205
149	Physical examinations of mental health service users. <i>Progress in Neurology and Psychiatry</i> , 2010, 14, 19-23.	0.4	6
150	Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 381, 427-439.	1.4	61
151	Smoking, nicotine and neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 295-342.	2.9	188
152	Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics. <i>Current Diabetes Reports</i> , 2010, 10, 209-216.	1.7	105
153	Prediction of the Period of Psychotic Episode in Individual Schizophrenics by Simulation-Data Construction Approach. <i>Journal of Medical Systems</i> , 2010, 34, 799-808.	2.2	6
154	Cardiovascular Risk Assessment and Management in Mental Health Clients: Whose Role is it Anyway?. <i>Community Mental Health Journal</i> , 2010, 46, 531-539.	1.1	27

#	ARTICLE	IF	CITATIONS
155	Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. <i>BMC Health Services Research</i> , 2010, 10, 61.	0.9	63
156	Care provided by general practitioners to patients with psychotic disorders: a cohort study. <i>BMC Family Practice</i> , 2010, 11, 92.	2.9	21
157	The development and evaluation of a complex health education intervention for adults with a diagnosis of schizophrenia. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2010, 17, 473-486.	1.2	25
158	Influence of a lifestyle intervention among persons with a psychiatric disability: a cluster randomised controlled trail on symptoms, quality of life and sense of coherence. <i>Journal of Clinical Nursing</i> , 2010, 19, 1519-1528.	1.4	82
159	Differential effects on T-cell function following exposure to serum from schizophrenia smokers. <i>Molecular Psychiatry</i> , 2010, 15, 364-371.	4.1	12
160	Promotion of physical wellbeing in schizophrenia and psychosis: implications for NHS trusts. <i>British Journal of Wellbeing</i> , 2010, 1, 31-35.	0.1	1
161	Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 304-311.	1.1	80
162	From patient to service user. <i>British Journal of Psychiatry</i> , 2010, 196, 353-353.	1.7	5
163	Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. <i>Journal of Psychopharmacology</i> , 2010, 24, 1001-1009.	2.0	26
164	What can we do to reduce the burden of avoidable deaths in those with serious mental illness?. <i>Epidemiologia E Psichiatria Sociale</i> , 2010, 19, 4-7.	1.0	13
165	Cigarette Smoking in Patients with Schizophrenia in China: Prospective, Multicentre Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 456-462.	1.3	27
166	Endocannabinoids and Schizophrenia. <i>Pharmaceuticals</i> , 2010, 3, 3101-3126.	1.7	27
167	Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2010, 196, 346-353.	1.7	69
168	Review: Cancer and schizophrenia: is there a paradox?. <i>Journal of Psychopharmacology</i> , 2010, 24, 51-60.	2.0	78
169	Review: Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?. <i>Journal of Psychopharmacology</i> , 2010, 24, 37-50.	2.0	80
170	Review: Mortality in schizophrenia: a measurable clinical endpoint. <i>Journal of Psychopharmacology</i> , 2010, 24, 17-25.	2.0	163
171	Nurses and Assertive Community Treatment Teams: A Critical Combination. <i>Issues in Mental Health Nursing</i> , 2010, 31, 751-752.	0.6	6
172	Schizophrenia: a multisystem disease?. <i>Journal of Psychopharmacology</i> , 2010, 24, 5-7.	2.0	18

#	ARTICLE	IF	CITATIONS
175	Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort. <i>Schizophrenia Research</i> , 2010, 116, 152-158.	1.1	65
176	Impact of the Spanish Consensus on Physical Health of Patients with Schizophrenia. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2010, 3, 119-127.	0.2	4
177	Physical health management in psychiatric settings. <i>European Psychiatry</i> , 2010, 25, S22-S28.	0.1	52
178	Development of a Health Screening Clinic. <i>European Psychiatry</i> , 2010, 25, S29-S33.	0.1	16
179	Clozapine and Cardiometabolic Health in Chronic Schizophrenia: Correlations and Consequences in a Clinical Context. <i>Australasian Psychiatry</i> , 2010, 18, 32-41.	0.4	11
180	Progress in Defining Optimal Treatment Outcome in Schizophrenia. <i>CNS Drugs</i> , 2010, 24, 9-20.	2.7	74
181	Changes in heart rate dynamics of patients with schizophrenia treated with risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 924-929.	2.5	37
182	Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. <i>Psychiatry Research</i> , 2010, 175, 38-42.	1.7	26
183	Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. <i>Psychiatry Research</i> , 2010, 176, 114-119.	1.7	9
184	Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 271-279.	1.7	125
186	Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation. <i>CNS Drugs</i> , 2010, 24, 193-206.	2.7	33
187	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011, 25, 567-620.	2.0	332
188	Prevention of Metabolic Syndrome in Serious Mental Illness. <i>Psychiatric Clinics of North America</i> , 2011, 34, 109-125.	0.7	17
189	Schizophrenia and Medical Illness: Is Medical Illness the Consequence of Schizophrenia or Its Treatment?. , 2011, , 267-287.		0
190	Effect of Antipsychotic Medications on Glucose and Lipid Levels. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 631-638.	1.0	52
191	Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study. <i>Schizophrenia Research</i> , 2011, 126, 110-116.	1.1	69
192	Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: A potential marker for cardiovascular morbidity?. <i>Schizophrenia Research</i> , 2011, 128, 44-50.	1.1	25
193	Effects of high aerobic intensity training in patients with schizophrenia—A controlled trial. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 269-275.	0.7	105

#	ARTICLE	IF	CITATIONS
194	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	4.8	631
197	Reliability, minimal detectable changes, practice effects and correlates of the 6-min walk test in patients with schizophrenia. <i>Psychiatry Research</i> , 2011, 187, 62-67.	1.7	53
198	Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia. <i>Psychiatry Research</i> , 2011, 190, 177-180.	1.7	22
201	P.8.a.007 Relationship of military adaptation with early-life stress and resilience in Korean young men. <i>European Neuropsychopharmacology</i> , 2011, 21, S614-S615.	0.3	1
202	The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 871-878.	1.1	38
203	Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. <i>European Psychiatry</i> , 2011, 26, 305-312.	0.1	15
204	The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management. , 0, , .		0
205	Will the changes to the QOF mental health indicators improve care for people with severe mental illness?. <i>British Journal of Wellbeing</i> , 2011, 2, 22-25.	0.1	1
206	Monitoring and Prevalence Rates of Metabolic Syndrome in Military Veterans with Serious Mental Illness. <i>PLoS ONE</i> , 2011, 6, e19298.	1.1	32
207	Autonomic Modulation and Health-Related Quality of Life among Schizophrenic Patients Treated with Non-Intensive Case Management. <i>PLoS ONE</i> , 2011, 6, e26378.	1.1	19
208	Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 86-91.	0.7	53
209	Barriers to Metabolic Care for Adults with Serious Mental Illness: Provider Perspectives. <i>International Journal of Psychiatry in Medicine</i> , 2011, 41, 379-387.	0.8	18
210	Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. <i>British Journal of Psychiatry</i> , 2011, 198, 434-441.	1.7	90
211	Incidence of Diabetes in Patients with Schizophrenia: A Population-Based Study. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 19-26.	0.9	25
212	Improving monitoring for metabolic syndrome using audit. <i>Irish Journal of Psychological Medicine</i> , 2011, 28, i-iv.	0.7	4
213	Improving the physical health of people with severe mental illness. <i>British Journal of Wellbeing</i> , 2011, 2, 32-34.	0.1	0
214	Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. <i>International Journal of Mental Health Nursing</i> , 2011, 20, 428-437.	2.1	54
215	Meanings of participating in a lifestyle programme for persons with psychiatric disabilities. <i>Scandinavian Journal of Caring Sciences</i> , 2011, 25, 357-364.	1.0	12

#	ARTICLE	IF	CITATIONS
216	Obstructive sleep apnoea and schizophrenia: a primer for psychiatrists. <i>Acta Neuropsychiatrica</i> , 2011, 23, 201-209.	1.0	5
217	Heart disease treatment and mortality in schizophrenia and bipolar disorder – Changes in the danish population between 1994 and 2006. <i>Journal of Psychiatric Research</i> , 2011, 45, 29-35.	1.5	79
218	Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia. <i>BMC Psychiatry</i> , 2011, 11, 188.	1.1	19
219	Risperidone in Schizophrenia: Is There a Role for Therapeutic Drug Monitoring?. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 275-283.	1.0	29
220	Overcoming splits in our understanding of schizophrenia and its management. <i>Progress in Neurology and Psychiatry</i> , 2011, 15, 6-7.	0.4	0
221	Quality Assessment of Physical Activity Recommendations Within Clinical Practice Guidelines for the Prevention and Treatment of Cardio-metabolic Risk Factors in People With Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 703-710.	1.1	21
222	Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 231-239.	1.8	33
223	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 417-423.	1.8	29
224	Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. <i>Psychopharmacology</i> , 2011, 217, 279-287.	1.5	60
225	Translation of the diabetes prevention program into a community mental health organization for individuals with severe mental illness: a case study. <i>Translational Behavioral Medicine</i> , 2011, 1, 453-460.	1.2	22
226	A well-being support program for patients with severe mental illness: a service evaluation. <i>BMC Psychiatry</i> , 2011, 11, 46.	1.1	36
227	Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. <i>Annals of General Psychiatry</i> , 2011, 10, 22.	1.2	41
228	Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC). <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1192-1198.	0.9	8
229	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	4.8	1,767
230	An oral pathogen and psychopathology severity in a sample of Arab patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2011, 18, 149-156.	0.5	0
231	Morbidity and mortality in schizophrenia. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 0,2	0.2	8
232	Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2011, 37, 352-361.	2.3	46
233	Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 192-202.	0.7	7

#	ARTICLE	IF	CITATIONS
234	Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. <i>Nordic Journal of Psychiatry</i> , 2011, 65, 40-46.	0.7	11
236	Cigarette Smoking and Mortality Risk in People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 832-838.	2.3	130
237	Health behaviour risk factors for coronary heart disease (CHD) in smokers with a psychotic disorder: baseline results. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 158-171.	0.5	16
238	Health behaviours of community-treated patients with psychosis. <i>Australasian Psychiatry</i> , 2012, 20, 208-213.	0.4	6
239	Metabolic syndrome in a sample of drug-naïve Egyptian patients with psychotic disorders. <i>Middle East Current Psychiatry</i> , 2012, 19, 23-31.	0.5	1
240	Is the use of an invitation letter effective in prompting patients with severe mental illness to attend a primary care physical health check?. <i>Primary Health Care Research and Development</i> , 2012, 13, 347-352.	0.5	12
241	Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 36-45.	0.7	54
242	Varenicline induced psychosis in schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1009-1009.	1.3	7
243	Adaptation to a Spouse's Disability by Parents of Adult Children With Mental Illness or Developmental Disability. <i>Psychiatric Services</i> , 2012, 63, 1118-1124.	1.1	19
244	An examination of the needs of older patients with chronic mental illness in public mental health services. <i>Aging and Mental Health</i> , 2012, 16, 327-334.	1.5	24
245	Special biological issues in the management of women with schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 823-833.	1.4	10
246	Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. <i>Psychological Medicine</i> , 2012, 42, 2275-2285.	2.7	88
247	Contingency Management for the Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Pilot Study. <i>Obesity Facts</i> , 2012, 5, 919-927.	1.6	18
248	Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week Open-Label Trial. <i>Journal of Dual Diagnosis</i> , 2012, 8, 117-125.	0.7	54
249	Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France. <i>International Psychogeriatrics</i> , 2012, 24, 496-502.	0.6	14
250	Common Use of Antipsychotic Polypharmacy in Older Asian Patients With Schizophrenia (2001-2009). <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 809-813.	0.7	16
251	Life expectancy and cardiovascular mortality in persons with schizophrenia. <i>Current Opinion in Psychiatry</i> , 2012, 25, 83-88.	3.1	426
252	Adherence to Antipsychotics and Cardiometabolic Medication: Association With Health Care Utilization and Costs. <i>Psychiatric Services</i> , 2012, 63, 920-928.	1.1	31

#	ARTICLE	IF	CITATIONS
253	Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. <i>European Heart Journal</i> , 2012, 33, 745-751.	1.0	78
254	Cardiovascular Mortality and Related Risk Factors among Persons with Schizophrenia: A Review of the Published Literature. <i>Public Health Reviews</i> , 2012, 34, .	1.3	3
255	QTc interval and its variability in patients with schizophrenia and healthy subjects: implications for a thorough QT study. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1535-1540.	1.0	6
256	Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 5-12.	0.9	62
257	International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. <i>Disability and Rehabilitation</i> , 2012, 34, 1-12.	0.9	122
258	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , 2012, 8, 114-126.	4.3	832
259	High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. <i>Schizophrenia Research</i> , 2012, 142, 52-57.	1.1	40
260	History of mental disorders and leukocyte telomere length in late adulthood: The Helsinki Birth Cohort Study (HBCS). <i>Journal of Psychiatric Research</i> , 2012, 46, 1346-1353.	1.5	35
261	Homelessness in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2012, 35, 717-734.	0.7	46
262	Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness. <i>Preventive Medicine</i> , 2012, 55, S54-S60.	1.6	25
263	Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. <i>World Psychiatry</i> , 2012, 11, 73-79.	4.8	233
264	Pharmacological treatment of schizophrenia. <i>International Review of Psychiatry</i> , 2012, 24, 489-498.	1.4	10
265	Role of Estrogen Treatment in the Management of Schizophrenia. <i>CNS Drugs</i> , 2012, 26, 549-557.	2.7	44
266	Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 169-175.	2.5	61
267	Mental Illness and Use of Screening Mammography Among Medicaid Beneficiaries. <i>American Journal of Preventive Medicine</i> , 2012, 42, 606-609.	1.6	29
268	Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. <i>Human Psychopharmacology</i> , 2012, 27, 521-526.	0.7	43
269	Modeling Interneuron Dysfunction in Schizophrenia. <i>Developmental Neuroscience</i> , 2012, 34, 152-158.	1.0	12
270	Cognitive deficits, obesity and disability in schizophrenia. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	8

#	ARTICLE	IF	CITATIONS
271	Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders. <i>Current Psychiatry Reports</i> , 2012, 14, 478-485.	2.1	55
272	Ziprasidone and the Corrected QT Interval. <i>CNS Drugs</i> , 2012, 26, 351-365.	2.7	41
275	INTERNATIONAL ORGANIZATION OF PHYSICAL THERAPY IN MENTAL HEALTH-CONSENSUS ON PHYSICAL ACTIVITY WITHIN MULTIDISCIPLINARY REHABILITATION PROGRAMMES FOR MINIMISING CARDIO-METABOLIC RISK IN PATIENTS WITH SCHIZOPHRENIA. <i>Schizophrenia Research</i> , 2012, 136, S47.	1.1	0
276	VOLUNTARY WHEEL RUNNING RESCUES CELLULAR AND BEHAVIORAL SCHIZOPHRENIC-LIKE PHENOTYPE IN MICE. <i>Schizophrenia Research</i> , 2012, 136, S47-S48.	1.1	0
278	Prevalence of High Blood Pressure and its Relationship with Body Weight Factors among Inpatients with Schizophrenia in Taiwan. <i>Asian Nursing Research</i> , 2012, 6, 13-18.	0.7	9
279	The incidence and relative risk of stroke in patients with schizophrenia: A five-year follow-up study. <i>Schizophrenia Research</i> , 2012, 138, 41-47.	1.1	47
280	Clinical characteristics of heavy and non-heavy smokers with schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 285-289.	1.1	19
281	Cardiovascular and cardiorespiratory coupling in unmedicated schizophrenic patients in comparison to healthy subjects. , 2012, 2012, 3664-7.		5
282	Cigarette Smoking in Male Patients with Chronic Schizophrenia in a Chinese Population: Prevalence and Relationship to Clinical Phenotypes. <i>PLoS ONE</i> , 2012, 7, e30937.	1.1	45
283	The Phrenic Component of Acute Schizophrenia – A Name and Its Physiological Reality. <i>PLoS ONE</i> , 2012, 7, e33459.	1.1	48
284	Comorbidity Profile and Healthcare Utilization in Elderly Patients With Serious Mental Illnesses. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	9
285	Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: preliminary study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012, 5, 389.	1.1	9
286	Network-Assisted Investigation of Antipsychotic Drugs and Their Targets. <i>Chemistry and Biodiversity</i> , 2012, 9, 900-910.	1.0	11
287	Efficacy of metformin for prevention of weight gain in psychiatric populations. <i>International Clinical Psychopharmacology</i> , 2012, 27, 69-75.	0.9	40
288	Developing a healthy living intervention for people with early psychosis using the Medical Research Council's guidelines on complex interventions: Phase 1 of the HELPER – InterACT programme. <i>International Journal of Nursing Studies</i> , 2012, 49, 398-406.	2.5	15
289	The heart of the matter: cardiometabolic care in youth with psychosis. <i>Microbial Biotechnology</i> , 2012, 6, 347-353.	0.9	82
290	Smoking, quitting, and psychiatric disease: A review. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 271-284.	2.9	198
291	Training practice nurses to improve the physical health of patients with severe mental illness: Effects on beliefs and attitudes. <i>International Journal of Mental Health Nursing</i> , 2012, 21, 259-265.	2.1	16

#	ARTICLE	IF	CITATIONS
292	Evolving role of mental health nurses in the physical health care of people with serious mental health illness. <i>International Journal of Mental Health Nursing</i> , 2012, 21, 266-273.	2.1	71
294	Polypharmacy in Psychiatry Practice, Volume II. , 2013, , .		2
295	Psychological and Psychiatric Triggers and Risk Factors for Stroke. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2013, , 255-297.	0.3	43
296	The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong – a cross sectional study. <i>BMC Psychiatry</i> , 2013, 13, 87.	1.1	29
297	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 283-287.	0.8	11
298	Smoking topography and outcome expectancies among individuals with schizotypy. <i>Psychiatry Research</i> , 2013, 205, 205-212.	1.7	9
299	Influence of <i>CRTC1</i> Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population. <i>JAMA Psychiatry</i> , 2013, 70, 1011.	6.0	42
300	Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. <i>Schizophrenia Research</i> , 2013, 150, 398-403.	1.1	40
301	Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. <i>BMC Psychiatry</i> , 2013, 13, 246.	1.1	21
302	Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. <i>Journal of Psychiatric Research</i> , 2013, 47, 1549-1556.	1.5	109
303	Cardiovascular coupling analysis with high-resolution joint symbolic dynamics in patients suffering from acute schizophrenia. <i>Physiological Measurement</i> , 2013, 34, 883-901.	1.2	39
304	Burden Of Schizophrenia On Selected Comorbidities Costs. <i>Value in Health</i> , 2013, 16, A12.	0.1	0
305	Guided exploration of genomic risk for gray matter abnormalities in schizophrenia using parallel independent component analysis with reference. <i>NeuroImage</i> , 2013, 83, 384-396.	2.1	48
306	Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. <i>Schizophrenia Research</i> , 2013, 148, 130-137.	1.1	205
307	The Deceleration Capacity - a New Measure of Heart Rate Variability Evaluated in Patients With Schizophrenia and Antipsychotic Treatment. <i>European Psychiatry</i> , 2013, 28, 81-86.	0.1	27
308	Cause-Specific Mortality Among Patients With Psychosis: Disentangling the Effects of Age and Illness Duration. <i>Psychosomatics</i> , 2013, 54, 536-545.	2.5	8
309	Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 187-192.	1.1	29
310	Comorbidity Profile and Healthcare Utilization in Elderly Patients with Serious Mental Illnesses. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 1267-1276.	0.6	78

#	ARTICLE	IF	CITATIONS
311	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013, 146, 190-195.	1.1	30
312	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: A Study Using the MATRICS Consensus Cognitive Battery. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 108-118.	0.6	68
313	Testing the Hypothesis of Accelerated Cerebral White Matter Aging in Schizophrenia and Major Depression. <i>Biological Psychiatry</i> , 2013, 73, 482-491.	0.7	107
314	After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health?. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013, 6, 26-32.	0.2	2
315	1784 " The characteristics of nicotine addiction among patients with schizophrenia. <i>European Psychiatry</i> , 2013, 28, 1.	0.1	0
316	Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness. <i>Psychosomatics</i> , 2013, 54, 67-73.	2.5	59
317	Lipid Effects of Psychiatric Medications. <i>Current Atherosclerosis Reports</i> , 2013, 15, 292.	2.0	2
318	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	1.3	22
319	Tras 6 meses de tratamiento antipsicótico: ¿mejor de la salud mental a costa de la salud física?. <i>Revista De Psiquiatria Y Salud Mental</i> , 2013, 6, 26-32.	1.0	8
320	Health promotion in mental health care: perceptions from patients and mental health nurses. <i>Journal of Clinical Nursing</i> , 2013, 22, 1569-1578.	1.4	42
321	Exercise Reveals the Interrelation of Physical Fitness, Inflammatory Response, Psychopathology, and Autonomic Function in Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2013, 39, 1139-1149.	2.3	37
322	Promoting mental and physical health in adults with psychosis. <i>Nursing Standard (Royal College of)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.1	0
323	Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients. <i>International Journal of Psychiatry in Medicine</i> , 2013, 45, 203-226.	0.8	14
324	Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. <i>American Journal of Psychiatry</i> , 2013, 170, 1451-1459.	4.0	95
325	Neuropsychiatric Symptoms of Cerebrovascular Diseases. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2013, , .	0.3	5
326	Healthy living? By whose standards? Engaging mental health service recipients to understand their perspectives of, and barriers to, healthy living.. <i>Psychiatric Rehabilitation Journal</i> , 2013, 36, 215-218.	0.8	14
327	Metabolic syndrome in schizophrenia: Theoretical, clinical and translational perspectives. <i>Indian Journal of Psychological Medicine</i> , 2013, 35, 117-120.	0.6	4
328	Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from India. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 21-29.	1.2	10

#	ARTICLE	IF	CITATIONS
329	Risks and Benefits of Bupropion Treatment in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2013, 36, 203-215.	0.2	20
330	Diagnostic Procedures, Revascularization, and Inpatient Mortality After Acute Myocardial Infarction in Patients With Schizophrenia and Bipolar Disorder. <i>Psychosomatic Medicine</i> , 2013, 75, 52-59.	1.3	44
331	The Evaluation of a Telephonic Wellness Coaching Intervention for Weight Reduction and Wellness Improvement in a Community-Based Cohort of Persons With Serious Mental Illness. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 977-986.	0.5	24
332	Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 740-746.	0.7	67
333	Metabolic Syndrome and the Risk of Suicide. <i>Psychosomatic Medicine</i> , 2013, 75, 807-814.	1.3	17
334	Separate and Combined Effects of Very Low Nicotine Cigarettes and Nicotine Replacement in Smokers with Schizophrenia and Controls. <i>Nicotine and Tobacco Research</i> , 2013, 15, 121-129.	1.4	54
335	Second-hand smoke in mental healthcare settings: time to implement total smoke-free bans?. <i>International Journal of Epidemiology</i> , 2013, 42, 886-893.	0.9	16
336	Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study. <i>American Journal of Psychiatry</i> , 2013, 170, 324-333.	4.0	491
337	Allostatic Load as a Tool for Monitoring Physiological Dysregulations and Comorbidities in Patients with Severe Mental Illnesses. <i>Harvard Review of Psychiatry</i> , 2013, 21, 296-313.	0.9	50
338	Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 125-130.	1.2	14
339	Cardiovascular health monitoring in patients with psychotic illnesses: A project to investigate and improve performance in primary and secondary care. <i>BMJ Quality Improvement Reports</i> , 2013, 2, u632.w640.	0.8	4
340	Reversed Shared Care in Mental Health: Bringing Primary Physical Health Care to Psychiatric Patients. <i>Canadian Journal of Community Mental Health</i> , 2013, 32, 1-16.	0.1	10
341	Effects of Hospitalization in a Psychiatric Ward on the Body Weight of Japanese Patients with Schizophrenia. <i>International Journal of Psychiatry in Medicine</i> , 2013, 45, 261-268.	0.8	1
342	Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. <i>BMC Psychiatry</i> , 2013, 13, 263.	1.1	28
343	Third sector facilitation of lived experience in research: a case study of service user and carer involvement in the PRIMROSE project. <i>Journal of Mental Health Training, Education and Practice</i> , 2013, 8, 141-151.	0.3	4
344	Dissecting the Obesogenic Environment of a Psychiatric Setting: Client Perspectives. <i>Canadian Journal of Community Mental Health</i> , 2013, 32, 51-68.	0.1	17
345	Cardiac autonomic dysregulation in acute schizophrenia. <i>Acta Neuropsychiatrica</i> , 2013, 25, 155-164.	1.0	24
346	Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 133.	1.0	8

#	ARTICLE	IF	CITATIONS
347	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 371.	1.0	20
348	The genomics of schizophrenia: update and implications. <i>Journal of Clinical Investigation</i> , 2013, 123, 4557-4563.	3.9	87
349	Investigation of Cigarette Smoking among Male Schizophrenia Patients. <i>PLoS ONE</i> , 2013, 8, e71343.	1.1	26
350	Smoking Cessation in Long-Term Conditions: Is There "An Opportunity in Every Difficulty"? <i>International Journal of Population Research</i> , 2013, 2013, 1-10.	0.7	4
351	The Characteristics of Nicotine Addiction Among Patients with Schizophrenia. , 0, , .		0
352	A Qualitative Study Exploring Facilitators for Improved Health Behaviors and Health Behavior Programs: Mental Health Service Users'™ Perspectives. <i>Scientific World Journal</i> , The, 2014, 2014, 1-7.	0.8	14
353	Cigarette smoking among psychiatric patients in Brazil. <i>Cadernos De Saude Publica</i> , 2014, 30, 1195-1206.	0.4	16
354	Obesity and Serious Mental Ill Health: A Critical Review of the Literature. <i>Healthcare (Switzerland)</i> , 2014, 2, 166-182.	1.0	46
355	The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1361.	1.0	10
356	Systematic computerised cardiovascular health screening for people with severe mental illness. <i>Psychiatric Bulletin (2014)</i> , 2014, 38, 280-284.	0.4	20
357	Coronary artery disease in adults with schizophrenia: Anatomy, treatment and outcomes. <i>International Journal of Cardiology Heart & Vessels</i> , 2014, 4, 84-89.	0.5	1
358	Neurodevelopmental and Neurodegenerative Models of Schizophrenia: White Matter at the Center Stage. <i>Schizophrenia Bulletin</i> , 2014, 40, 721-728.	2.3	186
359	Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. <i>Nutrition Journal</i> , 2014, 13, 91.	1.5	51
360	Effects of a group physical activity program on physical fitness and quality of life in individuals with schizophrenia. <i>Mental Health and Physical Activity</i> , 2014, 7, 155-162.	0.9	29
361	Effects of Smoking Abstinence on Cigarette Craving, Nicotine Withdrawal, and Nicotine Reinforcement in Smokers With and Without Schizophrenia. <i>Nicotine and Tobacco Research</i> , 2014, 16, 326-334.	1.4	44
362	Mitochondrial respiration in peripheral blood mononuclear cells correlates with depressive subsymptoms and severity of major depression. <i>Translational Psychiatry</i> , 2014, 4, e397-e397.	2.4	172
363	Adherence to Oral Diabetes Medications Among Users and Nonusers of Antipsychotic Medication. <i>Psychiatric Services</i> , 2014, 65, 215-220.	1.1	9
364	Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. <i>Frontiers in Psychiatry</i> , 2014, 5, 68.	1.3	24

#	ARTICLE	IF	CITATIONS
365	Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. <i>Frontiers in Physiology</i> , 2014, 5, 429.	1.3	94
366	Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions. <i>Frontiers in Psychiatry</i> , 2014, 5, 137.	1.3	247
367	Role of Atypical Antipsychotics in the Development of Metabolic Syndrome. <i>Current Approaches in Psychiatry</i> , 2014, , 1.	0.2	1
368	Physical performance and disability in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 112-121.	0.7	56
369	The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. <i>Current Medical Research and Opinion</i> , 2014, 30, 997-1005.	0.9	4
370	Burden of schizophrenia on selected comorbidity costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 259-267.	0.7	16
371	Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. <i>Pharmacogenomics</i> , 2014, 15, 61-67.	0.6	12
372	Cardiovascular risk factors among people with severe mental illness in Italy: A cross-sectional comparative study. <i>General Hospital Psychiatry</i> , 2014, 36, 698-702.	1.2	28
373	Cancer care for individuals with schizophrenia. <i>Cancer</i> , 2014, 120, 323-334.	2.0	134
374	The perceived risks and benefits of quitting in smokers diagnosed with severe mental illness participating in a smoking cessation intervention: Gender differences and comparison to smokers without mental illness. <i>Drug and Alcohol Review</i> , 2014, 33, 78-85.	1.1	13
375	High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 78-82.	1.0	18
376	ADHD and Nicotine Use in Schizophrenia or Asperger Syndrome. <i>Journal of Attention Disorders</i> , 2014, 18, 425-433.	1.5	6
377	Use of Medical Homes by Patients With Comorbid Physical and Severe Mental Illness. <i>Medical Care</i> , 2014, 52, S85-S91.	1.1	20
378	Quantitative Drug Benefit-Risk Assessment. <i>Annals of Pharmacotherapy</i> , 2014, 48, 306-313.	0.9	2
379	Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction. <i>Circulation</i> , 2014, 130, 235-243.	1.6	49
380	Body Mass Index, Obesity, and Psychopathology in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 40-46.	0.7	45
381	A Naturalistic Comparison of the Long-Term Metabolic Adverse Effects of Clozapine Versus Other Antipsychotics for Patients With Psychotic Illnesses. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 441-445.	0.7	18
382	Does training practice nurses to carry out physical health checks for people with severe mental illness increase the level of screening for cardiovascular risk?. <i>International Journal of Social Psychiatry</i> , 2014, 60, 236-242.	1.6	18

#	ARTICLE	IF	CITATIONS
383	Saffron Aqueous Extract Prevents Metabolic Syndrome in Patients with Schizophrenia on Olanzapine Treatment: A Randomized Triple Blind Placebo Controlled Study. <i>Pharmacopsychiatry</i> , 2014, 47, 156-161.	1.7	53
384	Eating Disorders in Schizophrenia: Implications for Research and Management. <i>Schizophrenia Research and Treatment</i> , 2014, 2014, 1-7.	0.7	54
385	Treatment resistance and other complicating factors in the management of schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 13-24.	0.7	7
386	Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: A case-control study. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2014, 7, 72-79.	0.2	6
388	Is low individual socioeconomic status (SES) in high-SES areas the same as low individual SES in low-SES areas: a 10-year follow-up schizophrenia study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 89-96.	1.6	15
389	Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 83-87.	1.8	45
390	Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. <i>Journal of Psychopharmacology</i> , 2014, 28, 349-356.	2.0	30
391	Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. <i>Microbial Biotechnology</i> , 2014, 8, 276-280.	0.9	20
393	Mortality in Schizophrenia: Clinical and Serological Predictors. <i>Schizophrenia Bulletin</i> , 2014, 40, 796-803.	2.3	38
394	Tobacco smoking in schizophrenia: investigating the role of incentive salience. <i>Psychological Medicine</i> , 2014, 44, 2189-2197.	2.7	11
395	Molecular pathophysiology of metabolic effects of antipsychotic medications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 593-600.	3.1	95
396	Phenotypic characteristics in metabolically healthy but obese patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 220, 71-75.	1.7	0
397	Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: Evidence from a national primary care database. <i>Schizophrenia Research</i> , 2014, 159, 176-181.	1.1	22
398	Cigarette smoking behaviors among adults with serious mental illness in a nationally representative sample. <i>Annals of Epidemiology</i> , 2014, 24, 776-780.	0.9	47
399	Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. <i>Psychopharmacology</i> , 2014, 231, 305-314.	1.5	12
400	Epigenetic Dysregulation in the Schizophrenic Brain. <i>Current Behavioral Neuroscience Reports</i> , 2014, 1, 86-93.	0.6	3
401	Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. <i>Journal of Psychiatric Research</i> , 2014, 48, 102-110.	1.5	204
402	Assessment of arterial stiffness among schizophrenia-spectrum disorders using aortic pulse wave velocity and arterial compliance: A pilot study. <i>Psychiatry Research</i> , 2014, 215, 14-19.	1.7	11

#	ARTICLE	IF	CITATIONS
403	Estado nutricional, ingesta alimentaria y riesgo de enfermedad cardiovascular en individuos con esquizofrenia en el sur de Brasil: estudio de casos-controles. Revista De Psiquiatría Y Salud Mental, 2014, 7, 72-79.	1.0	25
404	Examining the efficacy and feasibility of exercise counseling in individuals with schizophrenia: A single-case experimental study. Mental Health and Physical Activity, 2014, 7, 191-197.	0.9	18
405	Gender differences in characteristics and outcomes of smokers diagnosed with psychosis participating in a smoking cessation intervention. Psychiatry Research, 2014, 215, 586-593.	1.7	17
406	Accelerated white matter aging in schizophrenia: role of white matter blood perfusion. Neurobiology of Aging, 2014, 35, 2411-2418.	1.5	42
407	Unhealthy lifestyle in early psychoses: The role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology, 2014, 39, 1-10.	1.3	41
408	Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model. European Neuropsychopharmacology, 2014, 24, 448-458.	0.3	18
409	EPA Guidance on Tobacco Dependence and Strategies for Smoking Cessation in People with Mental Illness. European Psychiatry, 2014, 29, 65-82.	0.1	119
410	Multimodal white matter imaging to investigate reduced fractional anisotropy and its age-related decline in schizophrenia. Psychiatry Research - Neuroimaging, 2014, 223, 148-156.	0.9	37
411	Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. British Journal of Clinical Pharmacology, 2014, 77, 324-336.	1.1	103
412	A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population. Journal of Nutritional Science, 2015, 4, e28.	0.7	13
413	First Outpatient Follow-Up After Psychiatric Hospitalization: Does One Size Fit All?. Psychiatric Services, 2015, 66, 364-372.	1.1	38
414	Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study. Journal of Internal Medicine, 2015, 277, 727-736.	2.7	52
415	Schizophrenia and metabolic syndrome in rural communities: Understanding barriers and improving care.. Journal of Rural Mental Health, 2015, 39, 34-45.	0.5	3
416	Microvascular dysfunction in schizophrenia: a case-control study. NPJ Schizophrenia, 2015, 1, 15023.	2.0	16
417	Body mass, cardiovascular risk and metabolic characteristics of young persons presenting for mental healthcare in Sydney, Australia. BMJ Open, 2015, 5, e007066-e007066.	0.8	22
418	High-resolution joint symbolic analysis to enhance classification of the cardiorespiratory system in patients with schizophrenia and their relatives. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2015, 373, 20140098.	1.6	13
419	Understanding the Relationship Between Amphetamines and Psychosis. Current Addiction Reports, 2015, 2, 285-292.	1.6	21
420	Feasibility and acceptability of patient partnership to improve access to primary care for the physical health of patients with severe mental illnesses: an interactive guide. International Journal for Equity in Health, 2015, 14, 78.	1.5	23

#	ARTICLE	IF	CITATIONS
421	Association between concomitant psychiatric drug use, and patients' beliefs about and persistence with chronic cardiovascular medication. <i>International Journal of Clinical Practice</i> , 2015, 69, 328-335.	0.8	2
422	A pharmacogenomic study revealed an association between <i>SLC6A4</i> and risperidone-induced weight gain in Chinese Han population. <i>Pharmacogenomics</i> , 2015, 16, 1943-1949.	0.6	8
423	The perplexing issue of severe mental illness, physical health screening and primary care in England. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2015, 22, 647-652.	1.2	3
424	Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies. <i>Microbial Biotechnology</i> , 2015, 9, 357-362.	0.9	9
425	Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1493.	1.0	18
426	The Effect of Nicotine Dependence on Psychopathology in Patients with Schizophrenia. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	17
427	A systematic review and meta-analysis of exercise interventions in schizophrenia patients. <i>Psychological Medicine</i> , 2015, 45, 1343-1361.	2.7	447
428	Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study. <i>BMC Psychiatry</i> , 2015, 15, 67.	1.1	9
429	Breast Cancer Stage and Treatment Among Ohio Medicaid Beneficiaries With and Without Mental Illness. <i>Journal of Oncology Practice</i> , 2015, 11, e50-e58.	2.5	5
430	Factors Affecting Smoking Cessation Efforts of People With Severe Mental Illness: A Qualitative Study. <i>Journal of Dual Diagnosis</i> , 2015, 11, 42-49.	0.7	23
431	Smoking Cessation in Individuals With Serious Mental Illness: A Randomized Controlled Trial of Two Psychosocial Interventions. <i>Journal of Dual Diagnosis</i> , 2015, 11, 161-173.	0.7	10
432	Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 557.	0.7	22
434	Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 714-723.	1.3	11
435	Pilot intervention study of a low-salt diet with monomagnesium di-L-glutamate as an umami seasoning in psychiatric inpatients. <i>Psychogeriatrics</i> , 2015, 15, 38-42.	0.6	6
436	Analyses of Heart Rate, Respiration and Cardiorespiratory Coupling in Patients with Schizophrenia. <i>Entropy</i> , 2015, 17, 483-501.	1.1	32
437	Simvastatin augmentation for recent-onset psychotic disorder: A study protocol. <i>BBA Clinical</i> , 2015, 4, 52-58.	4.1	20
439	Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children. <i>Pharmacogenomics Journal</i> , 2015, 15, 95-100.	0.9	7
440	Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. <i>Pharmacogenomics</i> , 2015, 16, 981-996.	0.6	15

#	ARTICLE	IF	CITATIONS
441	High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. <i>Psychiatry Research</i> , 2015, 229, 295-301.	1.7	47
442	Cognitive Effects of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls. <i>Nicotine and Tobacco Research</i> , 2015, 17, 510-514.	1.4	29
443	Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. <i>Lancet Psychiatry</i> , the, 2015, 2, 452-464.	3.7	209
444	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. <i>Schizophrenia Research</i> , 2015, 164, 115-121.	1.1	13
445	Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls. <i>Schizophrenia Research</i> , 2015, 164, 47-52.	1.1	41
446	Individual Dietetic Consultations in First Episode Psychosis: A Novel Intervention to Reduce Cardiometabolic Risk. <i>Community Mental Health Journal</i> , 2015, 51, 211-214.	1.1	14
447	Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 323-330.	0.7	5
448	Polygenic risk scores in imaging genetics: Usefulness and applications. <i>Journal of Psychopharmacology</i> , 2015, 29, 867-871.	2.0	79
449	Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT. <i>Schizophrenia Research</i> , 2015, 164, 181-186.	1.1	19
450	Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats. <i>Psychopharmacology</i> , 2015, 232, 2877-2887.	1.5	5
451	Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. <i>Journal of Psychopharmacology</i> , 2015, 29, 1255-1261.	2.0	21
452	Excess non-psychiatric hospitalizations among employees with mental disorders: a 10-year prospective study of the GAZEL cohort. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 307-317.	2.2	2
453	P.3.c.006 Study of the protein expression levels in the pre-frontal cortex of mice subjected to haloperidol chronic exposure. <i>European Neuropsychopharmacology</i> , 2015, 25, S481-S482.	0.3	0
454	Mortality in Schizophrenia and Other Psychoses: A 10-Year Follow-up of the ÓSOP First-Episode Cohort. <i>Schizophrenia Bulletin</i> , 2015, 41, 664-673.	2.3	128
455	Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2015, 17, 80.	1.5	82
456	Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. <i>Journal of Endocrinology</i> , 2015, 227, 71-81.	1.2	25
458	Improved identification of people at risk of psychosis: is it value for money?. <i>Lancet Psychiatry</i> , the, 2015, 2, 951-952.	3.7	0
459	Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. <i>European Neuropsychopharmacology</i> , 2015, 25, 1-16.	0.3	75

#	ARTICLE	IF	CITATIONS
460	Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 25-36.	0.3	62
461	Analysis of heart rate variability during auditory stimulation periods in patients with schizophrenia. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 153-162.	0.7	26
462	Genes Associated with Increased Fasting Glucose in Patients with Schizophrenia Spectrum Disorders. <i>Journal of Diabetes & Metabolism</i> , 2016, 6, .	0.2	0
463	Epigenetic Approaches to Define the Molecular and Genetic Risk Architectures of Schizophrenia. , 2016, , 61-82.		1
464	Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 89-104.	1.4	321
465	Psychiatric comorbidities in patients with hypertension – a study of registered diagnoses 2009–2013 in the total population in Stockholm County, Sweden. <i>Journal of Hypertension</i> , 2016, 34, 414-420.	0.3	47
466	Introduction. <i>Harvard Review of Psychiatry</i> , 2016, 24, 77-79.	0.9	0
467	Smoking reduction and quality of life in chronic patients with schizophrenia in a Chinese population-A pilot study. <i>American Journal on Addictions</i> , 2016, 25, 86-90.	1.3	2
468	Resting-state high-frequency heart rate variability is related to respiratory frequency in individuals with severe mental illness but not healthy controls. <i>Scientific Reports</i> , 2016, 6, 37212.	1.6	52
469	Clozapine modifies the differentiation program of human adipocytes inducing browning. <i>Translational Psychiatry</i> , 2016, 6, e963-e963.	2.4	35
470	Aging in adults with intellectual disabilities and severe and persistent mental illness. , 2016, , 640-650.		0
472	Effects of antipsychotics on serum metabolic parameters in rats perinatally treated with phencyclidine. <i>European Neuropsychopharmacology</i> , 2016, 26, S260.	0.3	0
473	Quantitative EEG study of serotonergic hallucinogens in rats – the relationship of brain activity and behavior. <i>European Neuropsychopharmacology</i> , 2016, 26, S260-S261.	0.3	1
474	Implementation of a clinical practice guideline for schizophrenia in a specialist mental health center: an observational study. <i>BMC Health Services Research</i> , 2016, 16, 372.	0.9	14
475	Mental Health Issues and Special Care Patients. <i>Dental Clinics of North America</i> , 2016, 60, 551-566.	0.8	2
476	Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2016, 170, 290-300.	1.1	84
477	Smoking and its associations with sociodemographic and clinical characteristics and quality of life in patients with schizophrenia treated in primary care in China. <i>General Hospital Psychiatry</i> , 2016, 38, 79-83.	1.2	7
478	A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. <i>British Journal of Nutrition</i> , 2016, 115, 1987-1993.	1.2	51

#	ARTICLE	IF	CITATIONS
479	Psychological Distress and Hypertension: Results from the National Health Interview Survey for 2004-2013. <i>CardioRenal Medicine</i> , 2016, 6, 198-208.	0.7	39
480	Central- and autonomic nervous system coupling in schizophrenia. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2016, 374, 20150178.	1.6	35
481	Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1043-1053.	0.9	22
482	ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. <i>Biological Psychiatry</i> , 2016, 79, 952-961.	0.7	222
483	Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication. <i>Translational Psychiatry</i> , 2016, 6, e803-e803.	2.4	289
484	Prevalence of late potentials on signal-averaged ECG in patients with psychiatric disorders. <i>International Journal of Cardiology</i> , 2016, 222, 557-561.	0.8	9
485	Cannabis and a lower BMI in psychosis: What is the role of AKT1?. <i>Schizophrenia Research</i> , 2016, 176, 95-99.	1.1	11
487	Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia. <i>General Hospital Psychiatry</i> , 2016, 43, 46-50.	1.2	13
488	Incongruent changes in heart rate variability and body weight after discontinuing aerobic exercise in patients with schizophrenia. <i>International Journal of Psychophysiology</i> , 2016, 109, 132-137.	0.5	6
489	Managing diabetes in people with mental health problems. <i>NursePrescribing</i> , 2016, 14, 340-347.	0.1	0
491	Heterochronicity of white matter development and aging explains regional patient control differences in schizophrenia. <i>Human Brain Mapping</i> , 2016, 37, 4673-4688.	1.9	53
492	Elevated plasma F2-isoprostane levels in schizophrenia. <i>Schizophrenia Research</i> , 2016, 176, 320-326.	1.1	31
493	Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. <i>Current Medical Research and Opinion</i> , 2016, 32, 1873-1881.	0.9	15
494	Physical health promotion for young people at ultra-high risk for psychosis: An application of the COM-B model and behaviour change wheel. <i>International Journal of Mental Health Nursing</i> , 2016, 25, 536-545.	2.1	36
495	Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia. <i>International Journal of Social Psychiatry</i> , 2016, 62, 400-407.	1.6	5
496	Reduced cardiac autonomic response to deep breathing: A heritable vulnerability trait in patients with schizophrenia and their healthy first-degree relatives. <i>Psychiatry Research</i> , 2016, 243, 335-341.	1.7	14
497	Cancer in patients with schizophrenia: <sc>W</sc>hat is the next step?. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 473-488.	1.0	43
498	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. <i>CNS Spectrums</i> , 2016, 21, 393-402.	0.7	28

#	ARTICLE	IF	CITATIONS
499	Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders. <i>Neuropsychiatrie</i> , 2016, 30, 191-197.	1.3	2
500	Bifeprunox versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD012029.	1.5	4
501	Activity monitoring using a mHealth device and correlations with psychopathology in patients with chronic schizophrenia. <i>Psychiatry Research</i> , 2016, 246, 712-718.	1.7	19
502	Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2016, 16, 341.	1.1	139
503	Determinants of exercise intention and behaviour among individuals diagnosed with schizophrenia. <i>Journal of Mental Health</i> , 2016, 25, 303-309.	1.0	11
504	Prevalence, Patterns and Predictors of Psychotropic Polypharmacy Among Elderly Individuals with Parkinson's Disease In Long Term Care Settings In The United States. <i>Journal of Parkinson's Disease</i> , 2016, 6, 247-255.	1.5	7
505	The role of boundary spanners in delivering collaborative care: a process evaluation. <i>BMC Family Practice</i> , 2016, 17, 96.	2.9	15
506	Reliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar. <i>BMC Psychiatry</i> , 2016, 16, 437.	1.1	6
507	Somatic Care with a Psychotic Disorder. Lower Somatic Health Care Utilization of Patients with a Psychotic Disorder Compared to Other Patient Groups and to Controls Without a Psychiatric Diagnosis. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2016, 43, 650-662.	1.2	26
509	Atypical antipsychotics and effects on feeding: from mice to men. <i>Psychopharmacology</i> , 2016, 233, 2629-2653.	1.5	38
510	Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia. <i>International Journal of Social Psychiatry</i> , 2016, 62, 369-376.	1.6	7
511	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. <i>Journal of Psychopharmacology</i> , 2016, 30, 803-809.	2.0	19
512	Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016, 17, 80.	0.7	17
513	Cigarette and waterpipe smoking among adult patients with severe and persistent mental illness in Bahrain: a comparison with the National Non-communicable Diseases Risk Factors Survey. <i>BMC Research Notes</i> , 2016, 9, 77.	0.6	12
514	Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. <i>General Hospital Psychiatry</i> , 2016, 38, 9-14.	1.2	23
515	Cardiovascular diseases among patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2016, 19, 28-36.	0.9	46
516	Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in rats. <i>Behavioural Pharmacology</i> , 2016, 27, 321-330.	0.8	11
517	Reduced heart rate variability in schizophrenia and bipolar disorder compared to healthy controls. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 44-52.	2.2	58

#	ARTICLE	IF	CITATIONS
518	Smoking in male patients with schizophrenia in China: A meta-analysis. <i>Drug and Alcohol Dependence</i> , 2016, 162, 146-153.	1.6	36
519	Cannabis use in people with severe mental illness: The association with physical and mental health – a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study. <i>Journal of Psychopharmacology</i> , 2016, 30, 354-362.	2.0	29
520	The risk of thromboembolism in patients with schizophrenia. <i>International Journal of Cardiology</i> , 2016, 207, 375.	0.8	0
521	Comparison of Trends in Incidence, Revascularization, and In-Hospital Mortality in ST-Elevation Myocardial Infarction in Patients With Versus Without Severe Mental Illness. <i>American Journal of Cardiology</i> , 2016, 117, 1405-1410.	0.7	34
522	Resting vagal activity in schizophrenia: Meta-analysis of heart rate variability as a potential endophenotype. <i>British Journal of Psychiatry</i> , 2016, 208, 9-16.	1.7	122
523	Dysfunction in the coagulation system and schizophrenia. <i>Translational Psychiatry</i> , 2016, 6, e704-e704.	2.4	38
524	Evidence for Accelerated Decline of Functional Brain Network Efficiency in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 753-761.	2.3	39
525	Female schizophrenia patients and risk of breast cancer: A population-based cohort study. <i>Schizophrenia Research</i> , 2017, 188, 165-171.	1.1	35
526	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
527	Smoking Cessation: The Urgent Need for Increased Utilization of Varenicline. <i>American Journal of Medicine</i> , 2017, 130, 389-391.	0.6	8
528	Physical Health, Medication, and Healthcare Utilization among 70-Year-Old People with Schizophrenia: A Nationwide Danish Register Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 500-509.	0.6	18
529	Examining methods, messengers and behavioural theories to disseminate physical activity information to individuals with a diagnosis of schizophrenia: a scoping review. <i>Journal of Mental Health</i> , 2017, , 1-10.	1.0	1
530	Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. <i>World Psychiatry</i> , 2017, 16, 30-40.	4.8	477
531	Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care. <i>Comprehensive Psychiatry</i> , 2017, 74, 196-203.	1.5	21
532	Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. <i>Acta Pharmaceutica</i> , 2017, 67, 99-112.	0.9	3
534	A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 545-553.	1.3	47
535	Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan. <i>Psychological Medicine</i> , 2017, 47, 2483-2493.	2.7	15
536	Association of the type 2 diabetes mellitus susceptibility gene (IGF2BP2) with schizophrenia in an Egyptian sample. <i>Middle East Current Psychiatry</i> , 2017, 24, 55-62.	0.5	1

#	ARTICLE	IF	CITATIONS
537	Treating schizophrenia during menopause. <i>Menopause</i> , 2017, 24, 582-588.	0.8	34
538	A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 103-107.	0.7	4
539	Correlation between brain damage, associated biomarkers, and medication in psychiatric inpatients: A cross-sectional study. <i>Clinica Chimica Acta</i> , 2017, 464, 50-56.	0.5	3
540	Intranasal delivery of antipsychotic drugs. <i>Schizophrenia Research</i> , 2017, 184, 2-13.	1.1	41
541	Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. <i>Bipolar Disorders</i> , 2017, 19, 336-343.	1.1	52
542	Familial liability to psychosis is a risk factor for multimorbidity in people with psychotic disorders and their unaffected siblings. <i>European Psychiatry</i> , 2017, 45, 81-89.	0.1	8
543	Severe Mental Illness and Clinical Outcome After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 550-555.	0.7	21
544	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	6.0	135
545	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
546	Solving a weighty problem: Systematic review and meta-analysis of nutrition interventions in severe mental illness. <i>British Journal of Psychiatry</i> , 2017, 210, 110-118.	1.7	153
547	The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia. <i>Psychiatry Research</i> , 2017, 251, 131-136.	1.7	40
548	Psychiatric Care in Severe Obesity. , 2017, , .		3
549	Fluphenazine decanoate (timing of administration) for people with schizophrenia. <i>The Cochrane Library</i> , 2017, , .	1.5	1
550	Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. <i>Australasian Psychiatry</i> , 2017, 25, 387-390.	0.4	4
551	The epigenomics of schizophrenia, in the mouse. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 631-640.	1.1	12
552	Psychiatric conditions as predictors of rehospitalization among African American patients hospitalized with heart failure. <i>Clinical Cardiology</i> , 2017, 40, 1020-1025.	0.7	21
553	Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 958.	6.0	116
554	Advanced glycation end products among patients maintained on antipsychotics. <i>International Clinical Psychopharmacology</i> , 2017, 32, 256-261.	0.9	1

#	ARTICLE	IF	CITATIONS
555	Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia. <i>Journal of Medical Economics</i> , 2017, 20, 1252-1260.	1.0	12
556	Genetic variants of increased waist circumference in psychosis. <i>Psychiatric Genetics</i> , 2017, 27, 210-218.	0.6	4
557	Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 884-891.	0.7	18
558	Is cerebrovascular disease a silent condition in patients with chronic schizophrenia-related disorders?. <i>International Clinical Psychopharmacology</i> , 2017, 32, 80-86.	0.9	6
559	Exercise-induced modulation of histone H4 acetylation status and cytokines levels in patients with schizophrenia. <i>Physiology and Behavior</i> , 2017, 168, 84-90.	1.0	42
560	Challenges encountered in the conduct of Optimal Health: A patient-centered comparative effectiveness study of interventions for adults with serious mental illness. <i>Clinical Trials</i> , 2017, 14, 5-16.	0.7	9
561	Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 50-61.	0.6	77
562	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 317-335.	2.9	31
563	The physical health of Indigenous and non-Indigenous patients participating in residential rehabilitation programs: a comparison study. <i>Australasian Psychiatry</i> , 2017, 25, 164-167.	0.4	0
564	Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing physical activity among individuals with schizophrenia. <i>Schizophrenia Research</i> , 2017, 179, 2-7.	1.1	39
565	Cardiovascular risk screening for individuals with serious mental illness. <i>Social Work in Health Care</i> , 2017, 56, 809-821.	0.8	4
566	Assessing the second-hand effects of a new no-smoking policy in an acute mental health trust. <i>BJPsych Bulletin</i> , 2017, 41, 325-330.	0.7	2
567	Etiopathogenesis of metabolic syndrome in schizophrenia – recent findings. <i>Medicina</i> , 2017, 53, 27-42.	0.0	0
568	In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 424-431.	1.4	26
569	Cardiovascular disease in patients with schizophrenia. <i>Medical Journal of Australia</i> , 2017, 206, 91-95.	0.8	51
570	Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?. <i>Frontiers in Neuroscience</i> , 2017, 11, 155.	1.4	63
571	Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. <i>Frontiers in Neuroscience</i> , 2017, 11, 432.	1.4	55
572	Metabolic Effects of Antidepressant Treatment. <i>Noropsikiyatri Arsivi</i> , 2017, 54, 49-56.	0.7	21

#	ARTICLE	IF	CITATIONS
573	Association between antipsychotics and cardiovascular adverse events: A systematic review. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 261-267.	0.3	9
574	Framingham coronary score in individuals with symptoms or diagnoses of mental disorders: A review and meta-analysis. <i>Psychiatry Research</i> , 2018, 263, 41-47.	1.7	5
575	Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early Aging. <i>Annual Review of Clinical Psychology</i> , 2018, 14, 371-397.	6.3	122
576	Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. <i>Journal of Psychiatric Research</i> , 2018, 99, 50-61.	1.5	151
577	The impact of antipsychotics as a risk factor for thromboembolism. <i>Pharmacological Reports</i> , 2018, 70, 533-539.	1.5	24
578	Sensing Technologies for Monitoring Serious Mental Illnesses. <i>IEEE MultiMedia</i> , 2018, 25, 61-75.	1.5	80
579	Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. <i>Pharmacotherapy</i> , 2018, 38, 638-650.	1.2	11
580	Le vieillissement des personnes en situation de handicap mental et le cas particulier du syndrome de Down. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2018, 18, 69-77.	0.1	1
581	Nurse-Facilitated Health Checks for Persons With Severe Mental Illness: A Cluster-Randomized Controlled Trial. <i>Psychiatric Services</i> , 2018, 69, 601-604.	1.1	7
582	Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress?. <i>Schizophrenia Research</i> , 2018, 194, 98-106.	1.1	6
583	Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions. <i>Schizophrenia Bulletin</i> , 2018, 44, 398-408.	2.3	90
584	The association between cardio-respiratory fitness and cognition in schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 418-422.	1.1	11
585	A widening longevity gap between people with schizophrenia and general population: A literature review and call for action. <i>Schizophrenia Research</i> , 2018, 196, 9-13.	1.1	81
586	Elevation of plasma neutrophil gelatinase-associated lipocalin (NGAL) levels in schizophrenia patients. <i>Journal of Affective Disorders</i> , 2018, 226, 307-312.	2.0	18
587	The role of N-methyl-d-aspartate receptors and metabotropic glutamate receptor 5 in the prepulse inhibition paradigms for studying schizophrenia: pharmacology, neurodevelopment, and genetics. <i>Behavioural Pharmacology</i> , 2018, 29, 13-27.	0.8	13
588	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	1.5	7
589	Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. <i>Psychiatry Research</i> , 2018, 261, 243-247.	1.7	9
590	Temporal trends in cardiovascular disease risk factor profiles in a population-based schizophrenia sample: a repeat cross-sectional study. <i>Journal of Epidemiology and Community Health</i> , 2018, 72, 71-77.	2.0	5

#	ARTICLE	IF	CITATIONS
591	Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications. <i>Community Mental Health Journal</i> , 2018, 54, 717-724.	1.1	10
592	Childhood Adversity and Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	43
593	Can We Improve Physical Health Monitoring for Patients Taking Antipsychotics on a Mental Health Inpatient Unit?. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 447-453.	0.7	9
594	A Model of Enhanced Primary Care for Patients with Severe Mental Illness. <i>North Carolina Medical Journal</i> , 2018, 79, 240-244.	0.1	14
595	Major psychiatric disorders and the aetiology and progression of coronary heart disease. <i>British Journal of Cardiac Nursing</i> , 2018, 13, 446-454.	0.0	2
596	Investigating the Agreement Between Cardiovascular Disease Risk Calculators Among People Diagnosed With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 685.	1.3	11
597	Master's level mental health nursing competencies, a prerequisite for equal health among service users in mental health care. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2018, 13, 1502013.	0.6	7
598	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	1.3	115
600	Cross-tissue eQTL enrichment of associations in schizophrenia. <i>PLoS ONE</i> , 2018, 13, e0202812.	1.1	6
601	Effects of virtual reality exercise for Korean adults with schizophrenia in a closed ward. <i>Journal of Exercise Rehabilitation</i> , 2018, 14, 39-48.	0.4	7
602	Chromosomal Conformations and Epigenomic Regulation in Schizophrenia. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 157, 21-40.	0.9	16
603	The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance. <i>Frontiers in Pharmacology</i> , 2018, 9, 379.	1.6	23
604	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 203.	1.4	47
605	Metabolic Syndrome in First Episode Schizophrenia, Based on the National Mental Health Registry of Schizophrenia (NMHR) in a General Hospital in Malaysia: A 10-Year Retrospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 933.	1.2	12
606	Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia. <i>PLoS ONE</i> , 2018, 13, e0199922.	1.1	6
607	Collaborative, individualised lifestyle interventions are acceptable to people with first episode psychosis; a qualitative study. <i>BMC Psychiatry</i> , 2018, 18, 111.	1.1	8
608	Obstructive sleep apnoea is more prevalent in men with schizophrenia compared to general population controls: results of a matched cohort study. <i>Australasian Psychiatry</i> , 2018, 26, 600-603.	0.4	9
609	Risk factors for early circulatory mortality in patients with schizophrenia. <i>Psychiatry Research</i> , 2018, 267, 7-11.	1.7	23

#	ARTICLE	IF	CITATIONS
610	Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 474-484.	0.7	21
611	Coping strategies for oral health problems by people with schizophrenia. <i>Translational Neuroscience</i> , 2019, 10, 187-194.	0.7	4
612	Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. <i>Journal of Experimental Psychopathology</i> , 2019, 10, 204380871986569.	0.4	58
613	Impact of secondary care financial incentives on the quality of physical healthcare for people with psychosis: a longitudinal controlled study. <i>British Journal of Psychiatry</i> , 2019, 215, 720-725.	1.7	2
614	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. <i>Korean Journal of Family Medicine</i> , 2019, 40, 63-71.	0.4	13
615	Physical performance is more strongly associated with cognition in schizophrenia than psychiatric symptoms. <i>European Psychiatry</i> , 2019, 61, 72-78.	0.1	3
616	Altered Causal Coupling Pathways within the Central-Autonomic-Network in Patients Suffering from Schizophrenia. <i>Entropy</i> , 2019, 21, 733.	1.1	12
617	Clinical Correlates of Insulin Resistance in Chronic Schizophrenia: Relationship to Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2019, 10, 251.	1.3	13
618	Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. <i>BMC Psychiatry</i> , 2019, 19, 189.	1.1	43
619	Clinical determinants of physical activity and sedentary behaviour in individuals with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2019, 46, 62-67.	0.9	15
620	Gut microbiome in serious mental illnesses: A systematic review and critical evaluation. <i>Schizophrenia Research</i> , 2021, 234, 24-40.	1.1	47
621	Shared pathways for neuroprogression and somatoprogession in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 862-882.	2.9	74
622	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	1.1	32
623	Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. <i>Psychoneuroendocrinology</i> , 2019, 104, 42-48.	1.3	33
624	A novel biomarker of cardiometabolic pathology in schizophrenia?. <i>Journal of Psychiatric Research</i> , 2019, 117, 31-37.	1.5	10
625	Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. <i>Frontiers in Psychiatry</i> , 2019, 10, 103.	1.3	77
626	Metabolic Side Effects of Antipsychotic Medication: An Overview. <i>Journal of Korean Neuropsychiatric Association</i> , 2019, 58, 18.	0.2	0
627	QT dispersion and P wave dispersion in schizophrenia. <i>Journal of Theoretical Social Psychology</i> , 2019, 29, 538-543.	1.2	3

#	ARTICLE	IF	CITATIONS
628	The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 90.	1.3	7
630	Psychopathology and extrapyramidal side effects in smoking and non-smoking patients with schizophrenia: Systematic review and meta-analysis of comparative studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 476-482.	2.5	15
631	Sociodemographic, environmental characteristics and comorbidities of older adults with schizophrenia who access community health service support: A national cross-sectional study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 570-580.	1.3	5
632	Cardiovascular events in hospitalised patients with schizophrenia: a survival analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 106-113.	1.2	4
633	Cohort profile: Mental Health Living Longer: a population-wide data linkage to understand and reduce premature mortality in mental health service users in New South Wales, Australia. <i>BMJ Open</i> , 2019, 9, e033588.	0.8	9
634	Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. <i>International Clinical Psychopharmacology</i> , 2019, 34, 84-88.	0.9	8
635	Compliance in schizophrenia spectrum disorders. <i>International Clinical Psychopharmacology</i> , 2019, 34, 298-304.	0.9	6
636	Causes of Sudden Unexpected Death in Schizophrenia Patients. <i>American Journal of Forensic Medicine and Pathology</i> , 2019, 40, 312-317.	0.4	19
637	Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. <i>Behavior Therapy</i> , 2019, 50, 395-409.	1.3	16
638	Shared co-expression networks in frontal cortex of the normal aged brain and schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 253-261.	1.1	6
639	Cognitive functions in smoking and non-smoking patients with schizophrenia: A systematic review and meta-analysis of comparative studies. <i>Psychiatry Research</i> , 2019, 272, 155-163.	1.7	18
640	Preservation Effect: Cigarette Smoking Acts on the Dynamic of Influences Among Unifying Neuropsychiatric Triple Networks in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1242-1250.	2.3	36
641	Metabolic risk in patients participating in residential rehabilitation programs: how are we doing?. <i>Australasian Psychiatry</i> , 2019, 27, 179-182.	0.4	10
642	Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. <i>Psychiatric Quarterly</i> , 2019, 90, 351-359.	1.1	10
643	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 26-36.	2.2	30
644	Psychobiological response to an anger induction task in schizophrenia: The key role of anxiety. <i>Psychiatry Research</i> , 2019, 271, 541-547.	1.7	2
645	Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing sitting time among individuals with schizophrenia. <i>Psychiatry Research</i> , 2019, 271, 311-318.	1.7	11
646	The effect of schizophrenia on major adverse cardiac events, length of hospital stay, and prevalence of somatic comorbidities following acute coronary syndrome. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 121-126.	1.8	21

#	ARTICLE	IF	CITATIONS
647	Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia. <i>Psychiatric Quarterly</i> , 2019, 90, 29-40.	1.1	1
648	Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. <i>Schizophrenia Research</i> , 2019, 204, 23-29.	1.1	157
649	Brain insulin action in schizophrenia: Something borrowed and something new. <i>Neuropharmacology</i> , 2020, 163, 107633.	2.0	31
650	Brain insulin action: Implications for the treatment of schizophrenia. <i>Neuropharmacology</i> , 2020, 168, 107655.	2.0	19
651	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. <i>Neuropsychobiology</i> , 2020, 79, 5-12.	0.9	11
652	Physical Functional Limitations in a First-Admission Cohort at Midlife: Findings From the Suffolk County Mental Health Project. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1424-1430.	1.7	0
653	Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits. <i>Schizophrenia Research</i> , 2020, 215, 270-276.	1.1	23
654	Hidradenitis suppurativa and schizophrenia: a nationwide cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 574-579.	1.3	17
655	Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. <i>European Neuropsychopharmacology</i> , 2020, 32, 56-65.	0.3	20
656	Effects of therapeutic lifestyle change mentoring on cardio-metabolic factors for schizophrenia. <i>Archives of Psychiatric Nursing</i> , 2020, 34, 19-26.	0.7	0
657	Can high intensity interval training improve health outcomes among people with mental illness? A systematic review and preliminary meta-analysis of intervention studies across a range of mental illnesses. <i>Journal of Affective Disorders</i> , 2020, 263, 629-660.	2.0	28
658	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
659	Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. <i>Schizophrenia Research</i> , 2020, 216, 41-47.	1.1	13
660	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 43-57.	1.0	33
661	Targeted exon sequencing in deceased schizophrenia patients in Denmark. <i>International Journal of Legal Medicine</i> , 2020, 134, 135-147.	1.2	2
662	Increased ABCA1 (ATP-Binding Cassette Transporter A1)-Specific Cholesterol Efflux Capacity in Schizophrenia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2728-2737.	1.1	4
663	Heart rate variability is associated with disease severity in psychosis spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110108.	2.5	18
664	A cross-sectional study on metabolic similarities and differences between inpatients with schizophrenia and those with mood disorders. <i>Annals of General Psychiatry</i> , 2020, 19, 53.	1.2	3

#	ARTICLE	IF	CITATIONS
665	Higher risk of major adverse cardiac events after acute myocardial infarction in patients with schizophrenia. <i>Open Heart</i> , 2020, 7, e001286.	0.9	12
666	Cardio-metabolic abnormalities among patients with severe mental illness at a Regional Referral Hospital in southwestern Uganda. <i>PLoS ONE</i> , 2020, 15, e0235956.	1.1	3
667	Altered Autonomic Function in Individuals at Clinical High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 580503.	1.3	4
668	Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice. <i>BMC Family Practice</i> , 2020, 21, 153.	2.9	8
669	Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 129, 222-233.	1.5	23
670	The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting. <i>Journal of Psychiatric Research</i> , 2020, 129, 265-271.	1.5	4
671	Heart rate variability as an index of emotion (dys)regulation in psychosis?. <i>International Journal of Psychophysiology</i> , 2020, 158, 310-317.	0.5	10
672	Improving rates of metabolic monitoring on an inpatient psychiatric ward. <i>BMJ Open Quality</i> , 2020, 9, e000748.	0.4	6
673	Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2020, 16, 420-428.	0.7	7
674	The assertive cardiac care trial: A randomised controlled trial of a coproduced assertive cardiac care intervention to reduce absolute cardiovascular disease risk in people with severe mental illness in the primary care setting. <i>Contemporary Clinical Trials</i> , 2020, 97, 106143.	0.8	3
675	Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia. <i>BMC Health Services Research</i> , 2020, 20, 771.	0.9	4
676	Medical comorbidity among psychiatric patients treated at Jimma University Medical Center, Southwest Ethiopia: Retrospective record review. <i>Neurology Psychiatry and Brain Research</i> , 2020, 38, 33-38.	2.0	0
677	Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. <i>Nutrients</i> , 2020, 12, 3883.	1.7	15
678	Metabolic predictors for mortality among patients treated with long-term clozapine – A longitudinal study. <i>European Neuropsychopharmacology</i> , 2020, 41, 63-69.	0.3	10
679	Why are cardiovascular diseases more common among patients with severe mental illness? The potential involvement of electronegative low-density lipoprotein (LDL) L5. <i>Medical Hypotheses</i> , 2020, 142, 109821.	0.8	7
680	Time Trends in the Use of Coronary Procedures, Guideline-Based Therapy, and All-Cause Mortality following the Acute Coronary Syndrome in Patients with Schizophrenia. <i>Cardiology</i> , 2020, 145, 401-409.	0.6	7
681	Neurogranin regulates eNOS function and endothelial activation. <i>Redox Biology</i> , 2020, 34, 101487.	3.9	17
682	Oral health treatment habits of people with schizophrenia in France: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0229946.	1.1	14

#	ARTICLE	IF	CITATIONS
683	Retinal correlates of psychiatric disorders. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232090521.	1.1	29
685	The Cardiorespiratory Network in Healthy First-Degree Relatives of Schizophrenic Patients. <i>Frontiers in Neuroscience</i> , 2020, 14, 617.	1.4	3
686	The Role of Hippocampal Functional Connectivity on Multisystem Subclinical Abnormalities in Schizophrenia. <i>Psychosomatic Medicine</i> , 2020, 82, 623-630.	1.3	3
687	Pharmacotherapy for smoking cessation in schizophrenia: a systematic review. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 581-590.	0.9	12
688	Parental history of diabetes mellitus has additive risk of metabolic syndrome in patients treated with clozapine. <i>Asian Journal of Psychiatry</i> , 2020, 50, 101939.	0.9	0
689	Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness. <i>Contemporary Clinical Trials</i> , 2020, 91, 105964.	0.8	6
690	Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects. <i>Biological Psychiatry</i> , 2020, 88, 224-235.	0.7	52
691	Omega-3 fatty acids and mental health. <i>Global Health Journal (Amsterdam, Netherlands)</i> , 2020, 4, 18-30.	1.9	70
692	Late Potentials and Early Repolarisation Are Associated With Serious Mental Illness and May Portend Increased Arrhythmic Risk. <i>Heart Lung and Circulation</i> , 2020, 29, 1476-1483.	0.2	7
693	IGF2BP2 polymorphisms as genetic biomarkers for either schizophrenia or type 2 diabetes mellitus: A case-control study. <i>Gene Reports</i> , 2020, 20, 100680.	0.4	15
694	Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study. <i>Irish Journal of Psychological Medicine</i> , 2021, 38, 40-48.	0.7	10
696	Greater Arterial Stiffness in Children with or without Second-generation Antipsychotic Treatment for Mental Health Disorders: Rigidité Artérielle Plus Importante Chez Les Enfants Avec ou Sans Traitement Par Antipsychotiques de la Deuxième Génération Pour des Troubles de Santé Mentale. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 667-676.	0.9	2
697	An age-period-cohort analysis for prevalence of common psychiatric disorders in Japan, 1999–2017. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 639-648.	1.6	12
698	Gut microbiome in Schizophrenia: Altered functional pathways related to immune modulation and atherosclerotic risk. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 245-256.	2.0	44
699	The Gut Microbiome in Serious Mental Illnesses. <i>The Microbiomes of Humans, Animals, Plants, and the Environment</i> , 2021, , 243-263.	0.2	1
700	Identification of clinical phenotypes in schizophrenia: the role of lurasidone. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110122.	1.2	8
701	Psychiatric and Neurological Disorders. , 2021, , 117-141.		1
702	Hypothalamic Cell Models. , 2021, , 27-77.		0

#	ARTICLE	IF	CITATIONS
703	Electrocardiographic evaluation of the ventricular arrhythmia risk in patients with schizophrenia. <i>Anadolu Psikiyatri Dergisi</i> , 2021, 21, 1.	0.3	1
704	Psychotropic drug prescription patterns and their predictors among older adult patients with schizophrenia in a tertiary-referral psychiatric hospital. <i>Taiwanese Journal of Psychiatry</i> , 2021, 35, 70.	0.1	0
705	Smoking Cessation and Hospitalized Patients: A Missed Opportunity to Avoid Premature Deaths. <i>Ochsner Journal</i> , 2021, 21, 10-13.	0.5	1
706	Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 114-120.	0.7	10
707	Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: A Korean national cohort study. <i>Schizophrenia Research</i> , 2021, 228, 417-424.	1.1	15
708	Physical Activity Can Enhance Life (PACE-Life): results from a 10-week walking intervention for individuals with schizophrenia spectrum disorders. <i>Journal of Mental Health</i> , 2022, 31, 357-365.	1.0	7
709	Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. <i>Behavioural Brain Research</i> , 2021, 402, 113101.	1.2	28
710	Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis. <i>Irish Journal of Medical Science</i> , 2022, 191, 337-346.	0.8	3
711	Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta. <i>Biomolecules</i> , 2021, 11, 418.	1.8	2
712	The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review. <i>Systematic Reviews</i> , 2021, 10, 92.	2.5	21
713	Cardiovascular autonomic neuropathy in patients with schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2021, 75, 547-552.	0.7	1
714	Predicting Long-Term Outcomes in First-Admission Psychosis: Does the Hierarchical Taxonomy of Psychopathology Aid DSM in Prognostication?. <i>Schizophrenia Bulletin</i> , 2021, 47, 1331-1341.	2.3	9
715	Promoting physical health among people with enduring mental illness: a qualitative study of healthcare providers' perspectives. <i>BMJ Open</i> , 2021, 11, e044855.	0.8	3
716	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. <i>NPJ Schizophrenia</i> , 2021, 7, 22.	2.0	35
717	Subsequent Dyslipidemia and Factors Associated with Mortality in Schizophrenia: A Population-Based Study in Taiwan. <i>Healthcare (Switzerland)</i> , 2021, 9, 545.	1.0	0
718	Association between risk of dementia and very late-onset schizophrenia-like psychosis: a Swedish population-based cohort study. <i>Psychological Medicine</i> , 2023, 53, 750-758.	2.7	16
719	Prevalence of severe cardiovascular disease in patients with schizophrenia. <i>L'Encephale</i> , 2022, 48, 125-131.	0.3	5
721	Associations between symptom severity and well-being among Thai patients with schizophrenia: a cross-sectional analytical study. <i>BMC Psychiatry</i> , 2021, 21, 348.	1.1	0

#	ARTICLE	IF	CITATIONS
722	Mind-Body Connection: Cardiovascular Sequelae of Psychiatric Illness. <i>Current Problems in Cardiology</i> , 2022, 47, 100959.	1.1	8
723	Association of Mental Health Disorders and Aortic Dissection. <i>Annals of Vascular Surgery</i> , 2021, 77, 217-225.	0.4	6
724	Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. <i>Neuropsychopharmacology</i> , 2022, 47, 664-672.	2.8	19
725	Assertive Community Treatment Level Services for Older Adults with Severe Mental Illness: Exploration of Practitioners' Perspectives. <i>Journal of Psychosocial Rehabilitation and Mental Health</i> , 0, , 1.	0.4	0
726	Differential diagnosis and comorbid physical illness of schizophrenia. <i>Journal of the Korean Medical Association</i> , 2021, 64, 551-558.	0.1	0
727	Prevalencia en la prescripci3n de antipsic3ticos y monitoreo metab3lico en pacientes bajo tratamiento cr3nico. <i>Revista De La Facultad De Ciencias Medicas De Cordoba</i> , 2021, 78, 276-282.	0.1	2
728	Adiposity in schizophrenia: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 524-536.	2.2	19
729	Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 699748.	1.3	7
730	A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10016.	1.8	5
731	Comparison of three different exercise training modalities (aerobic, strength and mixed) in patients with schizophrenia: study protocol for a multicentre randomised wait-list controlled trial. <i>BMJ Open</i> , 2021, 11, e046216.	0.8	1
732	Chronic Stress, Exercise and Cardiovascular Disease: Placing the Benefits and Risks of Physical Activity into Perspective. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9922.	1.2	11
733	Editorial: Cardiovascular and Physical Health in Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2021, 12, 760250.	1.3	1
734	Aging biological markers in a cohort of antipsychotic-naïve first-episode psychosis patients. <i>Psychoneuroendocrinology</i> , 2021, 132, 105350.	1.3	7
735	Convolutional neural network in proteomics and metabolomics for determination of comorbidity between cancer and schizophrenia. <i>Journal of Biomedical Informatics</i> , 2021, 122, 103890.	2.5	10
736	Examining the feasibility, acceptability, validity and reliability of physical activity, sedentary behaviour and sleep measures in people with schizophrenia. <i>Mental Health and Physical Activity</i> , 2021, 21, 100415.	0.9	3
737	Menopause in women with schizophrenia, schizoaffective disorder and bipolar disorder. <i>Maturitas</i> , 2021, 152, 57-62.	1.0	12
738	Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. <i>Human Psychopharmacology</i> , 2021, 36, e2777.	0.7	5
739	Human Trafficking, Mental Illness, and Addiction: Avoiding Diagnostic Overshadowing. <i>AMA Journal of Ethics</i> , 2017, 19, 23-34.	0.4	26

#	ARTICLE	IF	CITATIONS
740	Management of Medication-Related Adverse Effects. , 2014, , 225-262.		1
741	Behavioural Interventions for Weight Management Among Patients with Schizophrenia. , 2017, , 257-273.		1
742	Psychosis and Schizophrenia. , 2008, , 371-389.		1
744	Cardiovascular risk assessment and management in mental health clients: Perceptions of mental health and general practitioners in New Zealand. Journal of Primary Health Care, 2009, 1, 11.	0.2	3
745	Effects of an 8-Week Aerobic Dance Program on Health-Related Fitness in Patients With Schizophrenia. The Journal of Nursing Research: JNR, 2017, 25, 429-435.	0.7	15
746	Effect of charted mental illness on reperfusion therapy in hospitalized patients with an acute myocardial infarction in Florida. Medicine (United States), 2017, 96, e7788.	0.4	3
747	No Increase in Suicide Risk Among Cardiopathic Patients. The American Heart Hospital Journal, 2007, 5, 103-106.	0.2	5
748	General Medical Problems of Incarcerated Persons With Severe and Persistent Mental Illness: A Population-Based Study. Psychiatric Services, 2010, 61, 45-9.	1.1	21
749	Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries. PLoS ONE, 2013, 8, e67133.	1.1	250
750	Prevalence and Correlates of Cigarette Smoking among Chinese Schizophrenia Inpatients Receiving Antipsychotic Mono-Therapy. PLoS ONE, 2014, 9, e88478.	1.1	25
751	Relative Risk of Acute Myocardial Infarction in People with Schizophrenia and Bipolar Disorder: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134763.	1.1	24
752	Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors. PLoS ONE, 2016, 11, e0149209.	1.1	33
753	Implementation of a smoke-free Psychiatric Unit in a general hospital. Revista Brasileira De Psiquiatria, 2010, 32, 197-198.	0.9	3
754	Dying young: Excess morbidity and mortality in individuals with severe mental illness and what we should be doing about it. University of Ottawa Journal of Medicine, 2014, 4, .	0.0	1
755	Key Workerâ€™Mediated Enhancement of Physical Health in First Episode Psychosis: Protocol For a Feasibility Study in Primary Care. JMIR Research Protocols, 2019, 8, e13115.	0.5	5
756	When Patients Train Doctors: Feasibility and Acceptability of Patient Partnership to Improve Primary Care Providers' Awareness of Communication Barriers in Family Medicine for Persons with Serious Mental Illness. Mental Health in Family Medicine, 2016, 12, .	0.2	1
757	Association Between Vitamin D Insufficiency and Metabolic Syndrome in Patients With Psychotic Disorders. Psychiatry Investigation, 2018, 15, 396-401.	0.7	8
758	Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues in Clinical Neuroscience, 2008, 10, 203-213.	1.8	28

#	ARTICLE	IF	CITATIONS
759	Epigenetic mechanisms in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 405-417.	1.8	74
760	Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. <i>Programme Grants for Applied Research</i> , 2019, 7, 1-98.	0.4	6
761	Weight Loss Interventions for Patients with Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 43-53.	1.4	7
762	Placebo-Controlled Trial of Atomoxetine for Weight Reduction in People with Schizophrenia Treated with Clozapine or Olanzapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 5, 17-25.	1.4	26
763	Adherence to Diabetes Medication in Individuals with Schizophrenia: A Systematic Review of Rates and Determinants of Adherence. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, 10, 191-200.	1.4	9
764	Topiramate in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 186-196.	1.4	21
765	Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. <i>Clinical Schizophrenia and Related Psychoses</i> , 2019, 12, 168-176.	1.4	18
766	Diabetes Resolution Following Discontinuation of a Second-Generation Antipsychotic. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 202-203.	1.4	5
767	Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients. <i>Global Health & Medicine</i> , 2020, 2, 178-183.	0.6	2
768	Comorbidities of Obesity in Serious Mental Illness. <i>Psychiatric Annals</i> , 2011, 41, 469-472.	0.1	2
769	Effects of Adjunctive Metformin on Metabolic Traits in Nondiabetic Clozapine-Treated Patients With Schizophrenia and the Effect of Metformin Discontinuation on Body Weight. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e424-e430.	1.1	62
770	Managing Antipsychotic Medications in Schizophrenia: Comprehensive Assessment and Personalized Care to Improve Clinical Outcomes and Reduce Costs. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1159-e1160.	1.1	5
771	Obesity in Patients With Severe Mental Illness. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 12-21.	1.1	71
772	Antipsychotic Adherence and Its Correlation to Health Outcomes for Chronic Comorbid Conditions. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	13
773	Increased Silent Brain Infarction Accompanied With High Prevalence of Diabetes and Dyslipidemia in Psychiatric Inpatients. <i>primary care companion for CNS disorders, The</i> , 2015, 17, .	0.2	5
774	Change in Framingham Risk Score in Patients With Schizophrenia. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006, 8, 329-33.	0.6	9
775	Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit. <i>Indian Journal of Psychiatry</i> , 2014, 56, 371.	0.4	12
776	Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. <i>Indian Journal of Psychiatry</i> , 2011, 53, 128.	0.4	43

#	ARTICLE	IF	CITATIONS
777	Prevalence and risk factors of metabolic syndrome among drug-naive psychotic patients. The Egyptian Journal of Psychiatry: Official Journal of the Egyptian Psychiatric Association, 2015, 36, 101.	0.1	2
778	Coronary artery disease as a cause of morbidity and mortality in patients suffering from schizophrenia: protocol for a prospective cohort study with long-term follow-up. Clinical Trials in Degenerative Diseases, 2016, 1, 141.	0.1	6
779	Increased Oxidant Stress and Inflammation in Patients with Chronic Schizophrenia. International Journal of Clinical Medicine, 2012, 03, 368-376.	0.1	11
780	Risk factors for respiratory disease in chronic psychiatric in patients. European Journal of Psychiatry, 2007, 21, .	0.7	2
782	Evaluation of Usefulness of Population Pharmacokinetics Analysis Results to Community Pharmacy-Effects of Smoking and Gender Difference on Olanzapine Dosages-. Iryo Yakugaku (Japanese) Tj ETQq0 000gBT /Overlock 10	0.0	0
783	Frequency of Cigarette Smoking Among Psychiatric Inpatients Evaluated by the Fagerstrom Test for Nicotine Dependence. Asian Pacific Journal of Cancer Prevention, 2013, 14, 579-582.	0.5	9
784	Assessing cardiovascular risk in patients with severe mental illness. Nursing Standard (Royal College) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
785	Improving medication-related outcomes for patients with psychiatric and neurologic disorders: Value of psychiatric pharmacists as part of the health care team. Mental Health Clinician, 2015, 5, 1-28.	0.5	34
786	Overcoming barriers to monitoring patients taking second-generation antipsychotics. Mental Health Clinician, 2018, 8, 49-55.	0.5	7
787	Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review. Clinical Psychopharmacology and Neuroscience, 2012, 10, 1-12.	0.9	9
788	Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics. Clinical Psychopharmacology and Neuroscience, 2018, 16, 32-38.	0.9	8
789	An integrative study of the microbiome gut-brain-axis and hippocampal inflammation in psychosis: Persistent effects from mode of birth. Schizophrenia Research, 2022, 247, 101-115.	1.1	7
790	Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: A cohort study in primary care. Psychiatry Research, 2021, 306, 114233.	1.7	4
791	Wellbeing for mind and body. Independent Nurse, 2007, 2007, .	0.0	0
792	Insulin Resistance in Schizophrenia, Major Depression, and Bipolar Disorder. , 2008, , 67-104.		0
793	Psychological Co-morbidities of Cardiovascular Disease. , 2011, , 123-162.		0
794	4. Physical Risks Induced by Novel Antipsychotics and Preventive Measures. Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 151-156.	0.1	0
795	Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial. Open Journal of Psychiatry, 2012, 02, 423-432.	0.2	0

#	ARTICLE	IF	CITATIONS
796	The general health of people with schizophrenia. , 2012, , 91-106.		0
797	The general health of people with schizophrenia. , 2012, , 91-106.		0
798	Metabolic Syndrome and Antipsychotic Polypharmacy. , 2013, , 145-155.		0
799	Mental Disorders - Theoretical and Empirical Perspectives. , 2013, , .		2
800	Management of Comorbid Medical Conditions in Schizophrenia. , 2014, , 175-204.		0
801	Physician Styles of Decision Making for a Complex Condition: Type 2 Diabetes with Comorbid Mental Illness. European Journal for Person Centered Healthcare, 2014, 2, 465.	0.3	3
802	Treating patients with antipsychotics: an individualized management. International Archive of Medicine, 0, , .	1.2	0
803	Genetics and Epigenetics in Cardiac Psychology. , 2015, , 1-17.		0
804	Reduced prevalence of cardiovascular disease and metabolic syndrome-related disorders among Japanese long-term inpatients with schizophrenia. Clinical Neuropsychopharmacology and Therapeutics, 2015, 6, 16-27.	0.3	0
805	Psychoses and Cardiovascular Disease: The Heart and Mind of the Matter. , 2015, , 1-14.		0
806	PREDICTORS OF READMISSION TO PSYCHIATRIC WARDS. Revista Debates Em Psiquiatria, 0, Ano 5, 6-8.	0.3	0
807	Haloperidol- induced cardiopulmonary arrest: a case report. Journal of Mood Disorders, 2016, 6, 29.	0.1	0
808	Genetics and Epigenetics in Cardiac Psychology. , 2016, , 789-805.		0
809	Psychoses and Cardiovascular Disease: The Heart and Mind of the Matter. , 2016, , 303-316.		1
810	Psychiatric Pharmacotherapy in Coronary Artery Disease Patients. , 2016, , 121-130.		0
811	Perfil socioeconômico, nutricional e fatores de risco cardiometabólico de pacientes esquizofrênicos em uso de antipsicóticos: uma reflexão para intervenções nutricionais. Revista Brasileira Em Promoção Da Saúde, 2016, 29, 60-67.	0.1	0
812	THE PROBLEM OF NEUROENDOCRINE DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER (literature review). Problemi Endokrinnoi Patologii, 2016, 57, 100-112.	0.0	0
813	The Role of Antipsychotic Medications in Metabolic Syndrome Amongst a Predisposed Population: Review of The Saudi Case. Journal of Metabolic Syndrome, 2017, 06, .	0.1	0

#	ARTICLE	IF	CITATIONS
816	Somatic Comorbidities in Psychiatric Patients. <i>Cardiologia Croatica</i> , 2017, 12, 275-281.	0.0	0
817	Do smoking assess in psychiatric outpatients?. <i>Konuralp Tip Dergisi</i> , 0, , 78-82.	0.1	2
818	Åžizofrenide GÅ¶rÅ¼len TÄ±bbi Durumlar. <i>Current Approaches in Psychiatry</i> , 2017, 9, 363-363.	0.2	1
819	Dimensions of improvement the physical health of people with mental illness. <i>PsihologÄCEÄ, ÄCE SuspÄCEIÊstvo</i> , 2018, 71-72, 143-154.	0.2	0
820	The evaluation of the nicotine dependence in psychiatric disorders. <i>Konuralp Tip Dergisi</i> , 0, , 48-54.	0.1	0
821	Antipsychotic Drug Therapies: Matching primary care practice to clinical challenges. <i>Archives of Community Medicine and Public Health</i> , 0, , 047-050.	0.1	0
822	Åžizofreni hastalarÄ±nda fiziksel hastalÄ±k eÅ¶ tanÄ±larÄ±nÄ±n deÄ¶lendirilmesi. <i>Cukurova Medical Journal</i> , 2018, 43, 892-902.	0.1	4
823	Fungal Infections of Central Nervous System and Their Relationship to Neuropsychiatric Disorders. , 2019, , 451-462.		0
824	Effect of MK-801 Treatment and Endurance Training on Angiogenic Response in Cardiac Muscle. <i>Exercise Science</i> , 2019, 28, 150-158.	0.1	0
825	Electrochemical Analysis of Antipsychotics. <i>Current Pharmaceutical Analysis</i> , 2019, 15, 413-428.	0.3	6
826	Improving the physical health of people with a mental illness: holistic nursing assessments. <i>Mental Health Practice</i> , 2019, 22, 34-41.	0.1	2
828	Comorbid Psychiatric and Physical Disorders. , 2020, , 205-228.		0
829	Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110464.	2.5	3
830	Antipsikotik Ä°laÅ¶ KullanÄ±mÄ±nÄ±n Elektrokardiyografi Parametreleri ile Ä°liÅ¶kisi-. <i>Current Approaches in Psychiatry</i> , 0, 11, 136-146.	0.2	1
831	Psychotische StÄ¶rungen und Schizophrenie. , 2020, , 947-1003.		0
832	Gender and Outcome in Schizophrenia. , 2020, , 15-25.		1
833	Weight change, cardio-metabolic risk factors and cardiovascular incidence in people with serious mental illness: protocol of a population-based cohort study in the UK from 1998 to 2020. <i>BMJ Open</i> , 2021, 11, e053427.	0.8	1
835	Mental Health and Sensing. <i>Intelligent Systems Reference Library</i> , 2021, , 247-260.	1.0	5

#	ARTICLE	IF	CITATIONS
836	Making room for mental health in the medical home. <i>Preventing Chronic Disease</i> , 2010, 7, A132.	1.7	7
837	The Northampton Physical Health and Wellbeing Project: the views of patients with severe mental illness about their physical health check. <i>Mental Health in Family Medicine</i> , 2012, 9, 233-40.	0.2	7
839	Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. <i>Journal of Research in Medical Sciences</i> , 2015, 20, 364-71.	0.4	9
840	Potential role of amino acids in pathogenesis of schizophrenia. <i>International Journal of Health Sciences</i> , 2017, 11, 63-68.	0.4	21
842	Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. <i>BMJ Open</i> , 2020, 10, e038013.	0.8	0
843	Assessment of Antipsychotic Medications on Social Media: Machine Learning Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 737684.	1.3	11
844	The intersection between childhood trauma, the COVID-19 pandemic, and trauma-related and psychotic symptoms in people with psychotic disorders. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab050.	0.9	5
845	Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. <i>BMJ Open</i> , 2020, 10, e038013.	0.8	4
846	Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 397-419.	0.8	20
847	Impairment of the cardiac ejection fraction by blocking dopamine D2 receptors induced by long-acting injectable antipsychotic treatment. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 497-508.	0.4	0
848	The additive impact of <sc>cardioâ€œmetabolic</sc> disorders and psychiatric illnesses on accelerated brain aging. <i>Human Brain Mapping</i> , 2022, 43, 1997-2010.	1.9	8
849	Frailty and severe mental illness: A systematic review and narrative synthesis. <i>Journal of Psychiatric Research</i> , 2022, 147, 166-175.	1.5	18
850	Effects of Aerobic, Resistance, and Combined Exercise Training on Psychiatric Symptom Severity and Related Health Measures in Adults Living With Schizophrenia: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 753117.	1.1	13
851	Genetic predisposition of BDNF (rs6265) gene is susceptible to Schizophrenia: A prospective study and updated meta-analysis. <i>NeurologAa</i> , 2022, , .	0.3	0
852	OCT and OCT Angiography Offer New Insights and Opportunities in Schizophrenia Research and Treatment. <i>Frontiers in Digital Health</i> , 2022, 4, 836851.	1.5	7
853	Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China. <i>Frontiers in Psychiatry</i> , 2022, 13, 754775.	1.3	2
854	Individuals to Systems: Methodological and Conceptual Considerations for Addressing Mental Illness Stigma Holistically. <i>International Journal of Mental Health and Addiction</i> , 2022, 20, 3368-3380.	4.4	5
855	Effect of Clinical Decision Support on Cardiovascular Risk Among Adults With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia. <i>JAMA Network Open</i> , 2022, 5, e220202.	2.8	11

#	ARTICLE	IF	CITATIONS
856	SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study. PLoS ONE, 2022, 17, e0264325.	1.1	3
857	The Ketogenic Diet in the Treatment of Schizophrenia. , 2022, , 229-244.		0
858	Schizophrenia: a disorder of broken brain bioenergetics. Molecular Psychiatry, 2022, 27, 2393-2404.	4.1	26
859	Association between retinal vascular measures and brain white matter lesions in schizophrenia. Asian Journal of Psychiatry, 2022, 70, 103042.	0.9	5
860	Comparison of frontal QRS-T angle in patients with schizophrenia and healthy volunteers. Journal of Psychiatric Research, 2022, 149, 76-82.	1.5	6
861	Allostatic load and systemic comorbidities in psychiatric disorders. Psychoneuroendocrinology, 2022, 140, 105726.	1.3	10
862	Sudden cardiac arrest in patients with schizophrenia: A population-based study of resuscitation outcomes and pre-existing cardiovascular disease. IJC Heart and Vasculature, 2022, 40, 101027.	0.6	1
863	Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life. Schizophrenia Research: Cognition, 2022, 28, 100245.	0.7	0
864	Part I: Interactive case: Adverse effects associated with antipsychotic therapy. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1618-1623.	0.5	0
868	Advanced Brain-Age in Psychotic Psychopathology: Evidence for Transdiagnostic Neurodevelopmental Origins. Frontiers in Aging Neuroscience, 2022, 14, 872867.	1.7	7
869	Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications. Psychiatry Research, 2022, 313, 114590.	1.7	1
870	New Paradigms of Old Psychedelics in Schizophrenia. Pharmaceuticals, 2022, 15, 640.	1.7	22
872	Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica, 2022, 146, 190-200.	2.2	5
873	Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal. Journal of International Medical Research, 2022, 50, 030006052211067.	0.4	5
874	Sudden Cardiac Death in Schizophrenia During Hospitalization: An Autopsy-Based Study. Frontiers in Psychiatry, 0, 13, .	1.3	2
875	Coexistence of mental and somatic diseases and difficulties in diagnosis and working with mentally ill people. Journal of Education, Health and Sport, 2022, 12, 649-659.	0.0	1
876	Neurogranin regulates calcium-dependent cardiac hypertrophy. Experimental and Molecular Pathology, 2022, 127, 104815.	0.9	3
877	The Mediating Role of Health-Promoting Behaviors on the Association between Symptom Severity and Quality of Life among Chinese Individuals with Mental Illness: A Cross-Sectional Study. Psychopathology, 2023, 56, 194-205.	1.1	0

#	ARTICLE	IF	CITATIONS
878	Peripheral inflammation levels associated with degree of advanced brain aging in schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
879	Association of Oxidative Stressâ€“Induced Nucleic Acid Damage With Psychiatric Disorders in Adults. <i>JAMA Psychiatry</i> , 2022, 79, 920.	6.0	12
880	Attentionâ€“deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide populationâ€“based cohort study. <i>World Psychiatry</i> , 2022, 21, 452-459.	4.8	27
881	Factors and their weight in reducing life expectancy in schizophrenia. <i>Schizophrenia Research</i> , 2022, 250, 67-75.	1.1	8
882	Responding to the Challenge of Multimorbidity in People with Serious Mental Illness. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 489-491.	0.2	2
883	Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study. <i>Nutrients</i> , 2022, 14, 5012.	1.7	2
884	Psychosis, antipsychotics and premature mortality: The elephant in the room. , 2016, 1, 11-17.		0
885	RÃ©duire le risque cardiovasculaire chez les personnes vivant avec des troubles psychiques. <i>Sante Publique</i> , 2022, Vol. 34, 633-642.	0.0	1
886	Psychosis iREACH: Reach for Psychosis Treatment using Artificial Intelligence. , 2022, , .		0
887	Propositions des professionnels pour rÃ©duire le risque cardiovasculaire des patients psychiatriques. <i>Sante Publique</i> , 2022, Vol. 34, 621-632.	0.0	0
888	Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). <i>BMJ Open</i> , 2023, 13, e068652.	0.8	3
889	Impact of Cognitive Disturbances and Clinical Symptoms on Disability in Patients with Paranoid Schizophrenia: A Study of a Bulgarian Clinical Sample. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2459.	1.2	1
890	The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
891	Healthy choices, healthy changes: A randomized trial of incentives to promote healthy eating and exercise in people with schizophrenia and other serious mental illnesses. <i>Schizophrenia Research</i> , 2023, 255, 1-8.	1.1	0
892	Choroidal structural analysis in ultra-high risk and first-episode psychosis. <i>European Neuropsychopharmacology</i> , 2023, 70, 72-80.	0.3	0
893	Atipik Antipsikotiklerle Tedavi SÃ¼recinde GÃ¼çlen Hiperhomosisteinemi Metabolik Sendromdan BaÅ±msÃ¼z. <i>Current Approaches in Psychiatry</i> , 2023, 15, 46-52.	0.2	0
894	Holistic assessment of patients with chronic mental disorders who attend a metabolic clinic in Sligo Town catchment area. <i>Irish Journal of Medical Science</i> , 0, , .	0.8	0
896	Brain deficit patterns of metabolic illnesses overlap with those for major depressive disorder: A new metric of brain metabolic disease. <i>Human Brain Mapping</i> , 2023, 44, 2636-2653.	1.9	1

#	ARTICLE	IF	CITATIONS
897	Interventions for Changing Brain Function in Clinical Disorders. , 0, 30, 90-102.		0
898	Attentionâ€deficit/hyperactivity disorder is associated with increased risk of cardiovascular diseases: A systematic review and metaâ€analysis. JCPP Advances, 2023, 3, .	1.4	7
899	The RAS-24: Development and validation of an adherence-to-medication scale for severe mental illness patients. Journal of Clinical and Translational Science, 2023, 7, .	0.3	0
932	Physical Health of Patients with Schizophrenia. , 2024, , 210-227.		0